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ABSTRACT 
Congenital malformations are important causes of perinatal mortality and morbidity, and around 4% of children 
are diagnosed with a malformation during their first year of life. Despite improved surgical treatment, several 
malformations are associated with lifelong sequelae requiring specialized health care. Important issues for these 
families are the etiology, prognosis and recurrence risk of the malformation in future pregnancies. Nowadays, 
around 50% of patients with malformations in combination with cognitive impairment receive an etiologic 
diagnosis after genetic evaluation. The aims of this thesis were to increase the knowledge of genetic causes 
behind congenital malformations, to improve clinical genetic investigations of these patients and at the same 
time to identify genes involved in normal and impaired organ development.  
Study I Whole-body human chimerism is the result of two zygotes giving rise to one individual, and is a rarely 
detected condition that can cause congenital anomalies. We have studied the molecular background of a 
46,XX/47,XY,+14 karyotype identified in clinical genetic investigation in a boy with disorder of sex 
development (DSD). Based on molecular findings, we suggest that the chimerism in our patient is the result of 
dispermic fertilization of a parthenogenetically activated oocyte. This study highlights chimerism as an 
underlying cause of distinct cell populations in an individual, and shows the difficulty of predicting the severity 
of associated phenotypes in mosaic or chimeric forms of genetic aberrations. 
Study II Tetrasomy 14 is a rare condition associated with multiple malformations, cognitive impairment and 
mortality when present in non-mosaic form. We report on molecular genetic and mitochondrial studies in an 8-
year-old girl with a marker chromosome 14. We showed that the marker chromosome originated from maternal 
meiosis and was present in all cells analyzed, providing evidence that survival beyond infancy is possible in non-
mosaic forms of this condition. The results emphasize importance of updating existing data on clinical outcomes 
of patients with severe diseases to correspond to high standard pediatric care. 
Study III VACTERL association is a condition with multiple malformations including vertebral (V) anorectal 
(A) cardiac (C) tracheoesophageal (TE) renal (L) and limb (L) anomalies, without a known common cause. We 
performed array comparative genomic hybridization (array CGH) and DNA sequencing of the candidate genes 
PCSK5, HOXD13 and CHD7 to investigate the role of copy number variants (CNV) and single gene defects in 
39 patients and fetal cases with VACTERL association or a VACTERL-like phenotype. We identified 
pathogenic gene dose alterations in 2/39 patients (5%) and a pathogenic mutation in CHD7 in one patient, while 
single nucleotide variants of unclear significance were detected in PCSK5. We concluded that copy number 
variants are not common causes of VACTERL association and that CHARGE and VACTERL syndromes 
represent important differential diagnoses. 
Study IV In this study, we have investigated the hypothesis that genetic mosaicism in malformed organs could 
be an underlying cause of congenital malformations. Array CGH analyses using DNA derived from cardiac 
tissue in 23 patients with congenital heart malformations were performed, and findings of pathogenic or unclear 
variants were compared with presence in blood in the same individuals. We identified pathogenic gene dose 
alterations in 2/23 patients (9%) and did not find evidence for mosaicism. We concluded that identification of 
copy number variants are important in individual cases of congenital malformations and that genetic mosaicism 
warrants further study using other molecular genetic technologies. 
Study V We have studied the presence of copy number variants in 25 patients with congenital anorectal 
malformations, esophageal atresia and hydronephrosis using array CGH analysis and identified pathogenic 
variants in 2/25 cases (8%). We describe a mosaic structural variant of tetrasomy 15 identified in a patient with 
syndromic esophageal atresia, and report a novel putative susceptibility region for esophageal atresia. Mosaicism 
for pathogenic or unclear variants was investigated in both tissue and blood in eight cases and did not reveal 
discrepancies. The study shows importance of copy number analysis in individual patients with gastrointestinal 
malformations. 
General conclusions from our studies are that tissue-specific genetic mosaicism for copy number variants does 
not appear to be a common cause of congenital malformations and that CNV analysis is important in patients 
with congenital malformations as identification of high penetrance variants in some families markedly improves 
accuracy of recurrence risk estimations in these families.
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1 INTRODUCTION 
1.1 EMBRYOLOGY AND CONGENITAL MALFORMATIONS 
1.1.1 Gametogenesis and fertilization 
The formation of a human embryo begins with the fusion of a female and a male gamete, an 
oocyte and a spermatozoon, and the development of these germ cells start in the early 
embryo. Precursor cells, primordial germ cells (PGCs), are formed in the epiblast layer of the 
embryo and migrate to the developing gonads which they reach 4-6 weeks after fertilization. 
During migration, and as resident cells of the gonads, the PGCs proliferate by mitosis and 
increase in number. The differentiation into female or male gametes depends on the 
surrounding gonadal tissue; PGCs in the developing ovary become oogonia while PGCs 
surrounded by testicular tissue become spermatogonia. Female and male gametogenetic 
processes have different characteristics, described below. 
1.1.1.1 Oogenesis 
In female gametogenesis (oogenesis), a mitotic expansion of the germ cells lead to a peak 
amount of almost 7 million germ cells around the 5
th
 fetal month, after which apoptosis starts, 
leaving around 2 million cells at birth (1). In the developing ovary, PGCs differentiate into 
oogonia and enter the first reduction division (meiosis I) becoming primary oocytes, the cell 
type that resides in the ovary until ovulation. Simultaneously, follicle formation starts and the 
oocytes become surrounded by somatic cells and form primordial follicles. During the 
remainder of fetal development, birth and childhood, a continuous reduction of the ovarian 
reserve through apoptosis of oogonia lead to a remainder of 200 000 follicles at the start of 
puberty (1). From the onset of puberty, hormonal stimulation leads to recruitment of groups 
of primordial follicles that mature in a process termed folliculogenesis. Primordial follicles 
are activated and with oocyte growth, granulosa cell proliferation and recruitment of stromal 
theca cells, they mature through different stages; primary follicles, secondary follicles, early 
antral follicles and preovulatory follicles, a process that takes around 6 months (2). Ovulation 
is finally induced by the peak increase of LH, when the follicle ruptures and the oocyte 
covered by granulose cells (the oocyte-cumulus complex) is released into the oviduct while 
the theca cells and remaining granulose cells of the follicle are converted to the progesterone 
and estradiol producing cells of the corpus luteum. During maturation of the oocyte, the 
volume increases about 100 fold and RNA and protein molecules required for growth of the 
cell accumulate in order to sustain the early development of an embryo in the event of 
fertilization (2). During maturation, the competence to complete meiosis is also acquired. 
This process is induced by the preovulatory LH peak, so that after ovulation, the released 
oocyte has entered into meiosis II and remains arrested at the metaphase stage.  
1.1.1.2 Spermatogenesis  
In contrast to oogenesis, much of the differentiation and growth in spermatogenesis take 
place after birth. In utero, PGCs entering testis migrate to the basal membrane of the 
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primitive sex cords where they rest until after birth, surrounded by supportive Sertoli cells 
that provide nutrients and a protective environment. Around six months after birth they 
differentiate into spermatogonia (3). Spermatogenesis starts in early puberty when the sex 
cords acquire a lumen and develop into the seminiferous tubules of the testis. In the lumen of 
the tubule, spermatogonia with retained stem cell function give rise to daughter cells 
committed to sperm development. These expand in number by mitotic divisions and 
differentiate from spermatogonia to primary and subsequently secondary spermatocytes, 
passing through meiosis I and II. Subsequently the spermatids develop acrosomal heads 
covering the nucleus, carrying enzymes for breakdown of the oocyte zona pellucida, and also 
the middle piece and tail structures. Mature spermatozoa are released into the lumen of the 
seminiferous tubules, leaving most of the cytoplasm behind, and are transported to the 
epididymis where they acquire full motility (4).  
1.1.1.3 Meiosis 
Differentiation of germ cells includes two reduction divisions, meiosis I and II, during which 
each daughter cell receives half the chromosomal content of the original cell. Mature human 
germ cells contain haploid genomes comprising 23 chromosomes (n) in contrast to diploid 
somatic cells that contain 46 chromosomes (2n). Meiosis differs from mitotic division, in 
which daughter cells normally receive the same amount of DNA material as that of the 
original cell, and also by the exchange of genetic material between chromosomes in a process 
called recombination. This exchange takes place during prophase of the first meiotic division, 
which comprises five phases that can be identified when dividing cells are studied in the 
microscope; leptotene, zygotene, pachytene, diplotene and diakinesis. Homologous 
chromosomes pair during the first meiotic division and are temporarily bound by 
synaptonemal complexes. Breaks in the DNA strands are introduced and the strands 
exchange their original “stem” chromosomes, resulting in new combinations of the two 
original homologous chromosomes. In this way the chromosomal content of the haploid 
genome of the mature germ cells become a mixture of the maternal and paternal homologues, 
and if fertilized results in contribution of a mixture of maternal and paternal genes to the new 
embryo. In a male germ cell approximately 52 chiasmatas, or crossings of chromosome arms, 
form per cell and are distributed with at least one chiasmata per chromosome arm (1). In 
meiosis, the sorting of chromosomes to the daughter cells adds an additional layer of genetic 
variation, as this occurs randomly and results in a mixture of maternal and paternal 
chromosomes in each germ cell. The timing and results of the meiotic divisions differ in 
oogenesis and spermatogenesis (Fig. 1).   




The spermatozoon is transported by movements of the uterus and oviduct as well as its own 
movement into the ampulla of the oviduct where fertilization often takes place (4). In the 
female genital tract, spermatozoa undergo a process called capacitation which is required for 
passage through the corona cells of the oocyte-cumulus complex. Upon interaction between 
spermatozoon and oocyte-cumulus complex, the acrosome reaction takes place, with release 
of enzyme-containing granules that aid the spermatozoon in the passage through the zona 
pellucida. Interaction with the zona pellucida also induces a protein modification reaction that 
inhibits additional sperm to fuse with the oocyte, as well as zona pellucida protein breakdown 
through protease activity (5), enabling the spermatozoon to come into contact with the oocyte 
membrane. After sperm adhesion to the oocyte, their germ cell membranes fuse and the head 
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and tail of the spermatozoon enter the oocyte cytoplasm (4). After sperm entry, the oocyte 
completes meiosis II, ending with expulsion of the second polar body. The remaining 
chromosomes are arranged in the female pronucleus, while the sperm nucleus forms the male 
pronucleus and the DNA of both pronuclei is replicated. During the earliest stages of embryo 
development, no zygotic gene transcription occurs and events are controlled by mRNA and 
proteins contributed by the oocyte, accumulated during oogenesis (6). The first mitoses of the 
embryo, the cleavage stage, take place without cell growth and result in reduction of cell 
sizes. Subsequently, zygotic gene transcription is initiated and maternal control of the embryo 
diminished. 
1.1.2 Genetic errors of gametogenesis 
Oogenesis and spermatogenesis render female and male gametes susceptible to distinct 
genetic abnormalities that can be transferred to the embryo and result in diseased offspring. 
The prolonged meiosis I of the oocyte is believed to render it susceptible to failed separation 
of homologous chromosomes at completion of meiosis I, so called non-disjunction, resulting 
in trisomy conceptions upon fertilization, a risk that increases distinctly at a maternal age of 
35 years. Consequently, the majority of the extra chromosomes 21 found in Down syndrome 
are of maternal origin. In contrast, spermatogenesis is characterized by a high number of 
replication cycles due to the many cell divisions required for lifelong sperm production, 
which increases the likelihood for introduction of replication based errors such as point 
mutations and CNVs (7). Indeed, 80% of de novo point mutations in patients with autism 
spectrum disorders and schizophrenia have been shown to be paternal in origin, and the 
frequency of total de novo mutations in offspring, unrelated to phenotype, increase with 
paternal age (8, 9). 
1.1.3 Embryogenesis 
During the development of the fertilized egg from a zygote to a full-grown fetus, different 
developmental periods can be defined. The embryonic period lasts from fertilization until the 
eighth week. Blastogenesis, ending with the formation of the three-layered embryo, takes 
place during the first two weeks. From the end of the second week until the eighth week, 
precursors of all organ systems are formed during organogenesis. The fetal period, which 
lasts from the ninth week until birth, is characterized by maturation and growth of the organs.  
After fertilization, the embryo develops into a morula at the 16-cell stage, when the cells 
separate into an inner cell mass (the embryoblast) giving rise to the embryonic structures, and 
an outer cell mass (the trophoblast), that contributes to the placenta. The morula develops into 
a blastocyst, visually characterized by a fluid-filled cavity, and after hatching from the zona 
pellucida, implantation into the uterine cavity starts. Cells of the trophoblast, called 
syncytiotrophoblast, invade the endometrial stroma while the embryoblast differentiates into 
two layers: the epiblast and the hypoblast. The syncytiotrophoblast invade the maternal 
capillaries in the uterine stroma and establishes a connection with the maternal blood flow 
that result in the first uteroplacental circulation. An important process in embryo development 
  11 
that takes place during this period is the determination of anterio-posterior, dorso-ventral and 
left-right body axis, which is a tightly coordinated event regulated by gene families important 
in embryological development. The embryo subsequently undergoes a process termed 
gastrulation, in which cells of the epiblast proliferate, migrate and invaginate through the 
primitive streak.  They subsequently form the three germ layers from which the different 
tissues and organ systems in the embryo develop during organogenesis; ectoderm, mesoderm 
and endoderm. The derivatives of the different germ layers are listed in Table 1. 
 
1.1.4 Normal and impaired organogenesis 
During the third week the notochord is formed in the mesodermal layer of the embryo. This 
midline signalling structure is crucial for folding and patterning of the embryo,. The 
notochord functions transiently during embryogenesis and produces developmentally 
important morphogens, such as the sonic hedgehog protein (SHH), that regulate development 
of surrounding tissues.  
During organogenesis the embryo undergoes a series of foldings in cephalo-caudal and lateral 
direction, resulting in formation of internal cavities and body wall closure. Development of 
some organs will be described briefly below. 
1.1.4.1 Development and malformations of the heart 
The heart is mainly formed from two different populations of mesodermal cells; the first and 
second heart field. Cells from the first heart field form the cardiac crescent in the cranial end 
of the embryonic disc. As a result of the cephalocaudal and lateral foldings of the embryo, the 
cardiac crescent fuses and forms the primitive heart tube. The second heart field is located 
medial to the cardiac crescent and contributes to most parts of the heart while the first heart 
field contributes to the left ventricle and atrial appendages (11). In addition, cells from the 
neural crest migrate into the region of the developing heart and contribute cells to the outflow 
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tract and the great arteries. The epicardium is formed from cells of the proepicardial organ 
(11). Formation of the heart is a complex three-dimensional morphogenetic process that 
results in the formation of two parallel circulations from the original “serial” circulation. The 
process involves looping of the cardiac tube, growth of endocardial cushions and formation 
of muscular contributions that participate in septation of atria, ventricles and great arteries 
and formation of the heart valves. The formation of the heart is regulated by temporally and 
spatially restricted gene expression, and biomechanical forces on the developing heart tissue, 
exerted by blood flow, also affects morphogenesis (12). 
Heart malformations are the most commonly diagnosed malformations, with an incidence of 
approximately 0.8% and can vary in clinical importance from subclinical to life-threatening 
(13). The most sensitive period in heart development is during the fifth week after 
fertilization (14). Malformations include different types of atrial and ventricular septal defects 
(ASDs and VSDs) that result from disturbances of the septation processes, and 
atrioventricular septal defect in which a common atrioventricular canal persists together with 
atrial and septal defects due to failure of fusion of the superior and inferior endocardial 
cushions. Failure of the outflow tract to form properly can result in a common arterious trunc 
(truncus arteriosus) instead of separation into aorta and the pulmonic trunc, or in transposition 
of the great arteries when the spiralling of the conotruncal septum is impaired causing the 
aorta to arise from the right ventricle and the pulmonary artery from the left. Tetralogy of 
Fallot is a sequence of structural anomalies caused by the unequal division of the conus 
region due to anterior displacement of the conotruncal septum, resulting in right ventricular 
outflow tract obstruction, a ventricular septal defect, displacement of the aorta to the right and 
right ventricular hypertrophy. Impaired development of the right atrioventricular valves may 
lead to tricuspid atresia, which can also be a part of the more complex Ebstein anomaly. 
Valvular stenosis of the semilunar valves in the aorta and pulmonary artery results from 
varying degrees of fusion of the valves, and depending on the degree of fusion can result in 
underdevelopment of the great vessel associated with the defect valves. Hemodynamic 
alterations leading to reduced aortic blood flow from the left ventricle are believed to affect 
development of the aorta and result in constriction of an aortic segment, coarctation of the 
aorta (Fig. 2).  
 
Many gene families are known to be involved in cardiac morphogenesis, and some of the 
most important known transcription factor families involved in heart development are 
NKX2.5, GATA4 and TBX1. 
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Treatment of different malformations varies from surgical repair within the first day after 
birth to none. Closure of ASD and dilatation of pulmonary valve stenosis can often be 
performed endoscopically, while repair or replacement of heart valves, dilatation of arteries 
and outflow tracts and repair of complex defects is performed with open heart surgery. 
1.1.4.2 Development and malformations of the gastrointestinal tract 
The primitive gut is formed when the embryonic disc undergoes cephalocaudal and lateral 
folding, by enclosure of part of the yolk sac cavity, lined by endoderm, into the developing 
embryo. The primitive gut stretches between the anterior oropharyngeal membrane and the 
posterior cloacal membrane and is divided into the foregut, midgut and hindgut. The 
endoderm gives rise to the epithelial lining of the intestine, lung, pancreas and thyroid and to 
parenchymal cells of the liver, while smooth muscle, connective tissue, the peritoneum and 
stromal components of the glands arise from visceral mesoderm. The foregut gives rise to the 
esophagus and future lung, with a tracheoesophageal septum gradually separating the future 
respiratory system from the esophagus. Both the stomach and the primary intestinal loop, 
arising from the midgut, undergo rotation during development. The hepatic diverticulum, or 
liver bud, arises from the end of the foregut. The hindgut extends into the cloaca, where the 
urorectal septum separates the dorsal anorectal canal from the ventrally located primitive 
urogenital sinus. The urorectal septum subsequently forms the perineal body between the 
openings of the urogenital sinus and the cloaca, the future urinary and fecal excretion 
systems. Gut connection with the surroundings is created by breakdown of the oropharyngeal 
and cloacal membranes later during development. 
Disturbances of gastrointestinal development can affect different parts of the system and 
result in malformations such as body wall defects (gastroschisis and omphalocele), 
malrotation of the primary intestinal loop and atresia of different parts of the gut. Esophageal 
and anal atresia will be described further below. 
Esophageal atresia (EA) 
Esophageal atresia is a malformation that occurs in 1/3 500 births and develops during the 
fifth week after fertilization (14, 15). 
The knowledge of the mechanisms that result in EA/TEF in these malformations is still very 
limited, although pathogenesis has recently been shown to involve disturbance in molecular 
specification of the ventral and dorsal walls of the foregut (16).  
Genes in which mutations are known to cause esophageal atresia include SOX2, MYCN and 
CHD7 (16).  
 14 
The malformation is surgically repaired with creation of an esophageal anastomosis within 
the first day after birth. The reported mortality is approximately 10% and is related to 
associated anomalies, compared to 100% mortality without surgery. Lifelong gastric and 
pulmonary complications are common in these patients (17).  
Anorectal malformations (ARM) 
Anorectal malformations occur in around 1/5 000 births and can present in a spectrum from 
imperforate anus with or without fistula (rectoperineal, vestibular, urethral or vesical) to 
cloacal malformation (18). The malformations result from abnormal development of the 
cloaca and urorectal septum during the seventh week after fertilization, but the pathogenic 
mechanisms behind the malformations are largely unknown.  
Genes in which mutations are known to cause syndromic ARM in humans include MNX1, 
SALL1 and GLI3, while mutations in HOXD13 have been described in a single patient (19, 
20). 
 Less severe anorectal malformations can be repaired in a single procedure after birth while 
patients with more severe forms receive a colostomy in the neonatal period until final repair 
can be performed at 1-2 months of age (18). The technique used for repair is called posterior 
sagittal anorectoplasty and involves division of the fistula, release of the gut and placement in 
normal position as well as creation of the pelvic floor muscles and external anal sphincter. 
Obstipation and urinary or fecal incontinence are common sequelae after surgery because of 
impaired development of the inner sphincter muscle and associated nerves. 
1.1.4.3 Development and malformations of the renal system 
The urological system originates from mesoderm, and two different transient systems (the 
pronephros and mesonephros) develop and regress before the permanent system is formed 
from the metanephros. The permanent collecting system including ureter, renal pelvis and 
calyces, develops from the ureteric bud which springs from the mesonephric (Wolffian) duct, 
invades the metanephric mesoderm and induces differentiation into renal parenchyma.  
Congenital Anomalies of the Kidney and the Urinary Tract (CAKUT) have an incidence of 
1/500 births (21). Disturbance of renal development during the fifth to eighth week can lead 
to uni- or bilateral renal agenesis with absence of ureter and kidney, if the ureteric bud fails to 
grow from the nephric duct. Inversely, duplex ureter and kidney, or duplex ureter and 
collecting system can result from growth of supernumerary ureteric buds. Impaired 
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interaction between the ureteric bud and the metanephric mesenchyme can result in renal 
hypodysplasia. Kidneys that are located more inferiorly than normally and are fused in the 
caudal lobes are called horseshoe kidneys. Impaired closure of the urinary bladder, bladder 
exstrophy, is a severe and very rare type of malformation (incidence of 1/10 000 to 1/50 000 
in live births) (22).  
 
Genes known to be involved in renal development and associated with human disease are the 
HNF1β, PAX2 and RET genes (21). 
While CAKUT can be subclinical, the more severe forms account for around 30% of renal 
failure in children, all of whom need to undergo renal replacement therapy (21). 
1.1.4.4 Development and malformations of the reproductive system 
Early gonads form as genital ridges in close relation to the mesonephros of the developing 
kidney, and primordial germ cells migrate to, and invade the ridges where they induce further 
gonadal development. Identical primitive genital structures develop in female and male 
embryos; bipotential gonads, genital ducts (Müllerian and Wolffian ducts) and external 
genitalia (genital tubercle, urethral folds and genital swellings) and all structures initially 
retain the possibility to develop into both female and male systems, depending on molecular 
signalling. In the event of female development, gonads differentiate into ovaries which 
produce estrogens that stimulate the Müllerian ducts to fuse and form female internal 
genitalia (the uterus, the oviducts and the upper part of the vagina) while the genital tubercle 
becomes the clitoris, the urethral folds become the labia minora and the genital swellings 
form the labia majora. In male development, gonads differentiate into testes that produce 
several important hormones; anti-Müllerian Hormone (AMH), which leads to regression of 
the Müllerian ducts and more importantly testosterone, which stimulates the Wolffian ducts 
to develop into the vas deferens, the rete testis, the epididymis and the seminal vesicle. 
External genitalia are stimulated by the testosterone metabolite dihydrotestosterone, which 
leads to elongation of the genital tubercle into the phallus, the formation of the penile urethra 
from the urethral folds and scrotal development from the genital swellings. The testes are 
formed in the abdomen, and during fetal development descend into the scrotum in two 
phases, both hormonally regulated from the testes. The transabdominal phase takes place 
between week 8 and 15 and is regulated by insulin-like hormone 3, while the second 
inguinoscrotal phase occurs between week 25 and 35 and is androgen-dependent (23).  
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Genital malformations in females 
Uterine malformations are reported in 4% of reproductive women, and are caused by 
impaired development or fusion of the Müllerian ducts in the female fetus (24). This can lead 
to complete uterine agenesis, duplications of the whole or part of the uterus (uterus didelphys 
or uterus bicornis) or failed reabsorption of the midline septum (septate uterus or arcuate 
uterus). Uterine malformations are associated with recurrent pregnancy loss, infertility and 
obstetric complications. For septate uterus, the delivery rate is as low as 40% untreated (24). 
Atresia of part of both Müllerian ducts can result in cervical atresia, and failed development 
or impaired fusion of the sinovaginal bulbs can cause vaginal atresia or duplication of the 
vagina, respectively.  
In many cases anatomically less complicated congenital uterine malformations, such as 
septate or arcuate uterus, may be treated surgically by hysteroscopy with drastic reduction of 
the risk for pregnancy loss. More complex malformations, such as uterus didelphys, may be 
associated with better pregnancy outcomes if not treated (25).  
Genital malformations in males 
The most common malformation of male genitalia is hypospadias, which occurs with an 
incidence of 8/1000 live-born boys in Sweden (26). Hypospadias results from incomplete 
fusion of the urethral folds that causes abnormal location of the urethral meatus at any point 
from the glans penis to the perineum along the ventral midline of the penis. Other features 
associated with hypospadias are ventral penile curvature (chordee) and cleaved ventral 
prepuce (27). Surgical repair, urethroplasty, is often performed between 6 and 18 months of 
age and can also include chordee excision, penile straightening, urethral, glanular and meatal 
reconstruction as well as skin reconstruction (27).  
A severe malformation is epispadias in which the urethral meatus is located on the dorsal side 
of the penis. This malformation is often associated with exstrophy of the bladder with 
incomplete closure of the body wall. Other penile malformations include micropenis, defined 
as 2.5 standard deviations below mean dorsal penile length, and bifid or duplicated penis as 
the result of a split genital tubercle. 
Disorders of sex development (DSD)  
DSD are defined as conditions when chromosomal, gonadal or anatomical sex is atypical, and 
the incidence of genital anomalies, when genitalia are not easily classified as male or female, 
is approximately 1/4 500 births (28). These conditions are classified into sex chromosome 
DSD, 46,XX DSD and 46,XY DSD. Chromosomal DSD includes 47,XXY (Klinefelter 
syndrome), 45,X (Turner syndrome), 45,X/46,XX and other mosaic or structural 
chromosomal aberrations leading to monosomy of whole or part of the X-chromosome, 
45,X/46,XY (mixed gonadal dysgenesis) and 46,XX/46,XY (mosaicism or chimerism) 
karyotypes (29). Both 46,XX and 46,XY DSD can be further classified into disorders of 
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gonadal development (gonadal dysgenesis, ovotesticular DSD as well as testicular DSD in 
46,XX and testis regression in 46,XY) disorders related to excess (46,XX) or deficit (46,XY) 
of androgens and other causes. DSD can lead to sterility, but in the most common form 
(under-masculinization of male fetuses) fertility is often unaffected. Importantly, gonadal 
dysgenesis is associated with a high risk for gonadal tumors (30). The treatment of 
individuals with DSD is complex with respect to gender assignment, hormone replacement, 
surgical as well as psychosocial management and is ideally handled by multidisciplinary 
teams at specialized units. 
Genes important in female development include WNT4 and DAX1 while and in male 
development SRY, WT1, SOX9, FGF9 and SF1 (4). 
1.1.4.5 Development and malformations of the vertebrae 
The vertebrae develop from somites, segments that form from mesoderm on either side of the 
notochord. Sclerotome cells from the somites migrate to meet cells from the opposing somite, 
surrounding the neural tube. The vertebrae are formed through resegmentation in which the 
caudal part of each somite grow into and fuse with the cranial part of its caudal neighbour 
while the mesenchyme in the middle of the initial segments remain and form part of the 
intervertebral discs.  
Vertebral malformations result from an abnormal formation or segmentation process of the 
somites during the fourth and fifth weeks after fertilization, and are reported in <1/1000 live 
births, but the true frequency is likely higher because of asymptomatic forms (31). Unilateral 
complete failure of formation results in different types of hemivertebrae, while partial failure 
can give rise to wedge vertebrae. Failure of midline fusion of the paired somite halves of the 
vertebrae can lead to development of so called butterfly vertebrae. Unilateral segmentation 
defects can result in unilateral unsegmented bars, while bilateral segmentation defects can 
result in block vertebrae. Vertebral anomalies are associated with development of scoliosis, 
kyphosis and back pain, especially the combination of a unilateral unsegmented bar and 
contralateral multiple segmented hemivertebrae. The simultaneous presence of rib anomalies 
can impair lung development (31).  
 
Genes important in vertebral development and associated with malformations in humans 
include HES7, DLL3 and MESP2 (31). 
Surgical procedures for congenital scoliosis include fusion procedures which may have side 
effects of restrictive lung disease, or procedures involving fixation material that allows 
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growth of the spine, with the downside of requirement for multiple surgical procedures and 
other complications (31).  
1.1.4.6 Development and malformations of the limbs 
The limbs develop from the limb buds that arise from the body wall, with a core forming 
from mesoderm and a cover of ectodermal cells. The forelimbs form before the hindlimbs. 
The growth of the limb buds is stimulated from the apical ectodermal ridge (AER), a 
signalling center at the distal end of the limb bud, and differentiation of the tissue into 
cartilage and muscle takes place in a proximal-to-distal direction. Development of the hands 
and feet involves apoptosis in the AER, leading to separation of tissue into the fingers and 
toes. Another signalling center, the zone of polarizing activity (ZPA), determines antero-
posterior patterning of the limb. Ossification of bones in the extremities takes place from 
ossification centers and starts at the end of the embryonic period. After birth, the diaphyses 
are often ossified but the epiphyseal plate is still cartilaginous and is responsible for growth 
of the long bones.  
Limb malformations occur during the sixth week after fertilization (14). The incidence of 
congenital upper limb malformations is 1-2/500 live births (32, 33), which is higher than for 
lower limb anomalies. Limb malformations can be classified into defects that result from 
failure of formation, failure of differentiation, duplication, over- or undergrowth, constriction 
ring syndrome or as a part of generalized abnormalities and syndromes (33). Limb 
malformations can affect a whole extremity as in amelia (absence of limb) or micromelia 
(underdevelopment of a limb) or only the long bones as in phocomelia (long bones shortened 
or absent in one or more extremities), hemimelia (shortening or absence of one of the long 
distal bones radius, ulna, tibia or fibula) or sirenomelia (fusion of the legs). Hand and foot 
anomalies include for example syndactyly (fusion of digits), poly- or hypodactyly (more or 
less than five digits), brachydactyly (short digits) and ectrodactyly (deficiency or absence of 
middle digits) (34).  
Genes known to be important in limb development, and that cause malformations in humans 
when mutated, include HOXD13, TBX4, TBX5 and FGF10 (4). 
Treatment options include correcting surgical procedures and custom-made prosthetic limbs 
in some cases, with the goal to improve function and life quality (34). 
1.1.5 Descriptive terms 
Congenital malformations are defined as primary structural defects that result from errors of 
morphogenesis (35). In comparison, secondary defects occur due to disruptions of normal 
morphogenesis, for example by teratogenic agents or trauma. Further, deformations are 
defined as alterations in shape or structure of normally formed fetal parts. In this thesis, the 
term malformation will be used for both primary and secondary defects, since the underlying 
causes of observed malformations are often unknown.  
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Malformations can occur isolated or in combination with other congenital abnormalities. A 
malformation sequence is a condition where one initial malformation leads to anomalies in 
other structures, whereas a malformation syndrome is a recognized pattern of malformations 
that occur as a response to one common cause. In cases with recognized malformation 
patterns where no common cause is known, the term malformation association is used. 
Description of congenital malformations includes different terms for failed or improper 
development. Agenesis is used to describe the absence or failed development of an organ due 
to absence of the embryologic primordium of the organ, for example renal agenesis. Atresia 
refers to the congenital absence of body openings or closure of tubular structures, e.g. anal 
and pulmonary atresia. 
1.1.6 Temporal effect 
Congenital malformations occur as a response to events that affect the embryonic or fetal 
period of development. The first two weeks after fertilization, are considered an “all-or-
nothing” period, when the cells of the embryo retain a high degree of potency and one cell 
can replace another in case of loss. However, if an insult occurs that leaves too many cells 
damaged, the embryo may be lost, although in some cases the result may not be lethal and 
may result in malformations (36, 37). During the period of organogenesis, when all organ 
systems are founded and the degree of cell differentiation is higher, the risk for organ 
malformations developing from embryonic insults is high. Early events before the end of the 
fourth week can result in severe neural, cardiac, gastrointestinal, renal and extremity defects 
while events in the second half of the organogenesis lead to milder defects. Insults during the 
fetal period, from the ninth week until birth, have less impact on organ development and are 
known to affect facial features, which can result in dysmorphism (38). 
1.1.7 Epidemiology 
Advances in pediatric surgery and intensive care have markedly increased survival among 
children with congenital malformations during the last decades, but congenital malformations 
are important causes of perinatal mortality and morbidity, and in Sweden, malformations or 
chromosomal aberrations are found in 30% of infants that die in the perinatal period (38). 
Severe birth defects in infants and aborted fetuses that are diagnosed within one month after 
birth are reported by neonatologists/pediatricians, obstetricians/gynecologists, pediatric 
cardiologists and cytogenetic laboratories to the Swedish Birth Defects Registry (SBDR), 
held by the National Board of Health and Welfare. In 2012, 2053 children (1.9%) were born 
with and 568 fetuses were aborted due to congenital malformations, though it should be noted 
that underreporting to this registry is a known problem. In addition, 183 children (0.2%) were 
born with and 408 fetuses were aborted due to chromosomal aberrations. Reported 
malformations were isolated (affecting one organ system) in 97% of children, and 60% of the 
reported children were male. Table 2 shows the reported number of cases of malformations in 
different organ systems in 2012 (39). Including less severe malformations, it is estimated that 
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around 4% of children have a malformation that is discovered during their first year of life 
(38). 
SBDR Swedish Birth Defects Registry. 
1Total number of births in 2012 was reported as 109 848. 
1.1.8 Causes of congenital malformations 
Following technical advances in molecular biology, the knowledge of the etiology behind 
congenital malformations has increased considerably. Still, the etiology can be determined in 
just over 50% of patients with congenital malformations in combination with developmental 
delay, and in a considerably lower proportion of patients with isolated malformations.  
Known causes of congenital malformations include genetic and environmental factors that 
influence organogenesis and cause fetal abnormalities. It has also long been suggested that 
combinations of genetic and environmental factors are responsible for disease.  
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1.1.8.1 Genetic causes 
Genetic aberrations of different size and type can cause congenital malformations and 
developmental delay. 
Chromosomal aberrations 
Losses and gains of chromosomal material that can be detected by chromosome analysis are 
large (≥~ 5 Mb) and are believed to affect embryonic development by changing the gene dose 
of many genes simultaneously, including developmentally important genes that are sensitive 
to gene dose alterations. 
Chromosomal aberrations usually affect neurological development and cause developmental 
delay and often malformations. Chromosomal aberrations include aneuploidies, with loss or 
gain of whole chromosomes, and deletions and duplications that affect parts of chromosomes. 
Constitutional aneuploidies seen in live-born children are trisomy 13, 18 and 21 and sex 
chromosome abnormalities, while other aneuploidies are not compatible with postnatal 
survival in constitutional form. Chromosomal translocations lead to different types of 
deletions and/or duplications that are most often unique to each family while other deletions 
or duplications are recurrent, such as Wolf-Hirschhorn syndrome (deletion of 4p) and cri du 
chat syndrome (deletion of 5p). Chromosomal aberrations can be caused by non-disjunction 
of homologous chromosomes or sister chromatids in the first or second meiotic divisions in 
parental germ cells in the case of aneuploidies, and from malsegregation of chromosomes 
resulting in unbalanced germ cells in translocation carriers. 
Microdeletions and microduplications 
Deletions and duplications smaller than 5 Mb can be detected by screening analyses such as 
array CGH or whole genome/exome sequencing, or by specific analyses such as FISH 
analysis, MLPA or quantitative PCR. Microdeletions and microduplications result in dose 
change for a lower number of genes compared to chromosomal aberrations and can affect 
development through several mechanisms: gene dose effect, position effects, gene disruptions 
or gene fusions. Recurrent microdeletions and microduplications are known causes behind 
malformation syndromes such as 22q11 deletion syndrome, Williams syndrome (deletion of 
7q11.2) and Potocki-Lupski syndrome (duplication of 17p11.2), while the effect of rare 
deletions and duplications are more difficult to predict. Microdeletions and microduplications 
that cause disease often occur de novo in affected individuals, but some pathogenic gene dose 
alterations are inherited from parents with the same or milder phenotypes (40). Gene dose 
alterations, or copy number variations, are further discussed in chapter 1.2.  
Single gene defects 
Mutations in single genes (insertions, deletions and base substitutions) can be detected by 
sequence analysis of specific genes and also by screening analysis using whole 
genome/whole exome approaches. Single gene mutations that lead to loss of function, gain of 
function or altered function can cause disease including malformations for example in 
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CHARGE syndrome (CHD7 mutations), Kabuki syndrome (KMT2D or KDM6A mutations) 
and Fanconi anemia (mutations in one of at least 15 different genes can cause disease). Single 
gene defects occur de novo or are inherited in a dominant, recessive or X-linked fashion. 
Imprinting 
Imprinting refers to a normal process that results in inactivation of alleles or regions of 
homologous chromosomes in a determined pattern dependent on the parental origin of the 
allele/homologous chromosome, and is thought to affect around 1% of human genes (38). 
Imprinted genes or regions are susceptible to disease in the case of deletion or inactivation of 
the active allele or gene region. In the 15q11-q12 region, some genes are imprinted on the 
maternal homologue while others are imprinted on the paternal homologue, and therefore 
deletion of the same genetic region can cause different phenotypic effects in individuals 
depending on the parental origin of the homologue that is affected by the deletion (Prader-
Willi and Angelman syndromes). Other examples of imprinting disorders are Beckwith-
Wiedemann and Silver-Russell syndromes. Imprinting disorders are sometimes caused by the 
phenomenon of uniparental disomy (UPD), in which case both homologues in a chromosome 
pair originate from the same parent.  
The de novo mutation concept 
A de novo mutation has been defined as “a genetic variation that is present for the first time in 
one family member (child) as a result of a mutation in a germ cell (egg or sperm) of one of 
the parents, or has occurred in the fertilized egg itself” (9) and are associated with sporadic 
disease as opposed to familiar disease caused by inherited mutations. Conclusions from 
massive parallel sequencing analysis in patient-parent trios in patients with 
neurodevelopmental phenotypes, is that de novo mutations in many different genes 
collectively represent an important role in phenotypes such as intellectual disability, autism 
spectrum disorders and schizophrenia (9). The importance of de novo mutations to a specific 
phenotype is proposed to correlate with the size of the mutational target (Fig. 7), the target 
mutability (highly mutable regions include CpG rich areas for point mutations and segmental 
duplications for CNVs) and paternal age at conception (point mutations and CNVs caused by 
replication-based mechanisms increase with paternal age) (7).  
With the new sequencing techniques, the estimation of de novo mutation frequencies per 
generation predicts 74 single nucleotide variants, 3 small insertions or deletions and 0.02 
CNVs per genome and one de novo mutation per exome (7). Overall mutation rates vary 
between and within families and are influenced by parental sex, age, ethnicity and 
predisposing genomic characteristics such as inversions, duplications, translocations and 
mutations in genes involved in DNA repair or recombination (7). Varying incidence rates for 
different recurrent genomic rearrangements mediated by NAHR can vary between ethnic 
groups because of ethnic-specific predisposing structural characteristics such as number of 
segmental duplications and their orientation in a specific region (7). 
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1.1.8.2 Environmental factors 
Embryological or fetal exposure to some environmental factors during sensitive time points 
in development can disrupt normal morphogenesis and result in secondary defects. Examples 
of teratogens, for which exposure during pregnancy increases the risk for malformations 
include maternal disease, drugs, radiation and industrial or agricultural chemicals.  
Maternal infection 
Several maternal infections are known to disturb embryonic and fetal development and cause 
abnormalities. Primary rubella infection in a non-vaccinated mother during the embryonic 
period (≤ 8 weeks) leads to malformations in 80% of cases and primarily causes heart defects, 
eye defects (congenital cataracts or retinopathy) and ear defects. Infection after 20 weeks of 
gestation is not associated with birth defects (41).  
Infection with cytomegalovirus (CMV), either primary or secondary, may cause a fetal 
infection that can lead to microcephaly, sensorineural hearing impairment and visual 
impairment due to chorioretinitis, optic atrophy or damage to the occipital cortex (42). 
Toxoplasma infection may also cause hearing and visual impairments in the fetus (43).  
Maternal chronic disease 
It is known that the risk for birth defects in pregnancies where the mothers have diabetes 
mellitus (including type I, II and gestational diabetes) is increased, especially the risk for 
heart malformations and neural tube defects. It has been proposed that increased glucose 
levels may affect the establishment of epigenetic patterns, leading to changed gene expression 
and abnormalities in the embryo (44).  
Other chronic diseases that seem to be associated with malformations independently of 
treatment are obesity (in absence of diabetes), migraine and paroxysmal supraventricular 
tachycardia (44, 45). 
Drug treatment 
Drugs are known teratogens that are believed to cause malformations through a number of 
disruptive mechanisms e.g. neural crest, endocrine or vascular disruptions, folate antagonism, 
oxidative stress or specific receptor- or enzyme-mediated teratogenesis (46). Different types 
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of drugs in clinical or recreational use are associated with fetal abnormalities, primarily 
cardiac abnormalities, for example chemotherapeutic agents (methotrexate), anticonvulsants 
(valproate), mood stabilizers (lithium), antibiotics (erythromycin), anticoagulants (warfarin) 
and retinoids (isotretionin) (35, 47-49). The knowledge of some such associations is used to 
choose alternative treatments if possible, although in severe cases the health of the pregnant 
woman is prioritized. Regarding recreational drugs, alcohol is a known teratogen and 
associations between maternal smoking and several different birth defects have been reported 
(50). 
Associations between drugs and birth defects are difficult to establish due to a number of 
inherent factors. Malformations are rare events, and associations are therefore most 
efficiently studies by case-control studies, which may introduce selection and exposure 
information may be subject to observation bias. Also, many factors may affect outcomes, for 
example multiple drug treatment, timing of fetal exposure, dosage level and underlying 
genetic predisposition. In addition, the disease for which the pregnant woman is treated may 
in itself increase the risk for fetal abnormalities.  
Assisted reproductive technologies (ART) 
Conflicting evidence has been presented as to whether assisted reproduction techniques using 
in vitro fertilization (IVF) increase the risk for birth defects (51). It is proposed that the 
observed slightly elevated risk for major malformations seen in ARF pregnancies that has 
been presented in recent studies (3-4% as opposed to 2-3% for a normal population) may be 
explained by an inherent higher risk for birth defects in couples receiving ART treatment, and 
not related to the procedure (51). 
Radiation 
Exposure of the fetus to high doses of radiation increases risk for microcephaly and other 
birth defects. However, fetal anomalies are only associated with exposure to more than 50 
mGy, which is a dose markedly higher than the radiation exposure for the fetus at singular 
examinations using radiography, computed tomography or nuclear medicine (52).  
Industrial and agricultural chemicals 
An example of a teratogenic agricultural chemical is methyl mercure, a metal compound used 
to preserve seed grain, and methyl mercury poisoning in pregnant women is known to 
increase the risk for birth defects (35). 
1.1.8.3 Multifactorial etiology 
A multifactorial model of inheritance, in which genetic and environmental factors add up to a 
threshold over which morphogenesis results in a malformation, has been proposed for many 
isolated congenital malformations, on the basis of statistical evidence (53, 54). This 
mechanism is proposed to explain the occurrence of phenotype in families with non-
Mendelian inheritance and sporadic disease. Still it is possible that di-, oligo- or polygenic 
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causes can explain familial occurrence, and sporadic disease may be caused by de novo 
mutations.  
1.2 COPY NUMBER VARIATION 
1.2.1 Definition 
Structural variation in the human genome includes balanced (inversions and balanced 
translocations) and unbalanced forms (deletions, duplications and insertions) in terms of copy 
number, which refers to the number of times a specific genomic region occurs in a genome 
(55). Unbalanced forms, copy number variants (CNVs), were initially defined as stretches of 
DNA more than 1000 bp (1 kb) in size that differ in copy number in relation to a reference 
genome (56), but since refined methods, including high-throughput paired-end sequencing, 
have shown copy number variants of smaller sizes, a later definition refers to CNVs as ≥ 50 
bp in size (55).  
Copy number variation was first described in 2004, when technologies allowing comparison 
of whole genome copy number patterns between different genomes emerged. Two different 
studies described that segments of DNA, in size between small variants affecting base pairs 
and large variants such as heteromorphisms, were scattered over large regions of the human 
genome and contributed to genetic variation (57, 58). It is believed that CNVs cover 5-12% 
of the human genome and they probably account for 0.5-1% of the genetic variation between 
two individuals (59, 60). In an evolutionary perspective, it is likely that copy numbers with 
genetic content have inferred evolutionary benefits that have lead to enrichment in the human 
genome. Different types of CNVs are shown in figure 8.  
 
1.2.2 Phenotypic influence of CNVs 
CNVs are believed to affect phenotypes by changing gene expression, and studies have 
shown that expression of genes within and in the vicinity of CNVs are affected by copy 
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number variants (61). More than 50% of the effects of known CNVs are caused by gene 
disruption or disruption of the regulatory units associated with genes, rather than by gene 
dosage change (40). Changing the regulatory landscapes of genes can lead to a variety of 
effects since changes can be tissue- or developmental stage-specific (55). Interestingly, it 
seems that changed mRNA levels correspond poorly with protein levels, due to the several 
levels of regulation that determine protein levels (55). In general, it seems that deletions have 
more severe effect on human phenotypes than duplications, since 80% of CNVs reported in 
the Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl 
Resources (DECIPHER, https://decipher.sanger.ac.uk/) are deletions and that the duplications 
listed are correlated to less severe symptoms (62). 
Recurrent microdeletions and microduplications were first identified as causes of 
developmental disease, and rare CNVs are also known to be responsible for disease 
phenotypes (63-65). Lately, CNVs have been implicated in complex diseases, for example 
Parkinson disease, Alzheimer disease, schizophrenia, HIV susceptibility and Crohn’s disease 
(63).  
Importantly, the term CNV is a structurally descriptive term that implies presence of varying 
copy number for a specific region, but does not confer information about clinical 
significance. In order to specify clinical impact, CNVs should be defined as benign or 
pathogenic (66).  
1.2.3 Mechanisms behind formation of CNVs 
Genome-wide studies have estimated that de novo CNVs > 100 kb occur in 1/50 individuals 
(67). Different mechanisms for formation of CNVs have been described, with different types 
of mechanisms responsible for recurrent and rare CNVs. 
Non-allelic homologous recombination (NAHR) 
This mechanism involves recombination between non-homologous sequences of high 
similarity present in the genome, mostly segmental duplications or low-copy repeats which 
are > 10 kb in length and show 95-97% sequence similarity and therefore confer risk for 
erroneous pairing during recombination. Repeats oriented in the same direction mediate 
formation of duplications and deletions of the interval between the repeats, while repeats 
oriented in opposite directions mediate formation of inversions. NAHR can occur during 
meiosis and mitosis and lead to constitutional or somatic, often recurrent, CNVs (63). 
Non-homologous end-joining (NHEJ) 
This mechanism is used to repair double-stranded breaks in chromosomes caused by 
environmental factors, and physiologically in B and T cells for creation of receptor and 
immunoglobulin diversity.  CNVs resulting from NHEJ are non-recurrent and often found in 
shorter repeat sequences such as LINEs, Alu repeats and LTRs. A molecular “scar” with 
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inserted nucleotides can often be identified. This mechanism can cause deletions and 
translocations, but not duplications. 
Fork Stalling and Template Switching (FoSTeS)/Microhomology-mediated break-induced 
replication (MMBIR) 
The FoSTeS mechanism is active during DNA replication and involves fork stalling, 
disengagement of the lagging strand and association with a new replication fork, induced by 
microhomology sequences. This process may be repeated several times which can lead to 
complex rearrangements, and is responsible for deletions, duplications and inversions. 
Another replication-based mechanism that involves template-switching is MMBIR which is 
activated by breakage of a single DNA strand at the replication fork (63). 
1.3 VACTERL ASSOCIATION 
VACTERL association is a congenital heterogeneous condition with multiple malformations 
affecting different organ systems in affected individuals, and has an estimated incidence of 
1/10 000-1/40 000 in different studies (68). The component features of VACTERL are 
vertebral defects (V), anal atresia (A), cardiac malformations (C), tracheo-esophageal fistula 
(T) with esophageal atresia (E), renal malformations (R) and limb defects (L). The condition 
was first described by Quan and Smith more than 40 years ago (69), and was then termed 
VATER and included vertebral, anorectal, tracheoesophageal and radial anomalies while 
cardiac and renal anomalies were later added. Neurocognitive disability is not considered part 
of the phenotypic spectrum, although a specific form of VACTERL, VACTERL-H, includes 
hydrocephalus due to aqueductal stenosis (OMIM:#276950) (68). VACTERL association 
usually occurs sporadically, although familial cases exist (70).  
Diagnostic criteria, which are debated, include malformations in three of the organ systems, 
on the prerequisite that other malformation syndromes are not more likely causes. Due to the 
unknown cause, the heterogeneous phenotype and the phenotypic overlap with many other 
malformations syndromes, it is considered a diagnosis of exclusion (71). The clinical picture 
varies with the severity of the malformations seen in different individuals, and can differ from 
subclinical to life-threatening. Due to improvements in health care during the last decades, 
prognosis is rather good with present surgical techniques and intensive care, although 
sequelae cause substantial morbidity. 
1.3.1 Causes of VACTERL association 
There is no known, unifying cause of VACTERL association. It is generally believed to be a 
causally heterogeneous condition, although it is still possible that a single cause may explain 
the majority of cases, as in the case with CHD7 in CHARGE syndrome. Genetic, 
environmental and multifactorial causes have been proposed as causative.  
1.3.1.1 Genetic factors 
Evidence for one or more genetic causes includes (14):  
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1) an increased incidence of one or more component features in first-degree relatives of 
patients with VACTERL association (72) which implies genetic components in at 
least a subset of cases 
2) second-degree relatives show component features of VACTERL association 
3) several chromosomal aberrations have been reported in single patients (70) 
4) mutations in single genes have been described in individual patients  
5) overlap between the phenotype seen in VACTERL association and several other 
malformation syndromes caused by single gene defects 
6) VACTERL-like phenotypes are observed in mouse studies with mutations in genes 
(Shh, Gli2, Gli3, Pcsk5) involved in the embryologically important sonic hedgehog 
(SHH) signalling pathway (73, 74)  
It is worth noting that despite overlap with other syndromes, there is no single syndrome that 
encompasses all VACTERL component features except for VACTERL-H, which in some 
cases is caused by mutations affecting the FANC genes and has once been reported in patient 
with a heterozygous mutation in the PTEN gene (75, 76). A mutation in the ZIC3 gene, 
normally associated with heterotaxy, has also been reported in a patient with all component 
features of VACTERL association (14). 
Causative genetic factors that are compatible with findings of low monozygotic concordance 
in twins and sporadic occurrence are for example single gene defects with reduced penetrance 
or variable expressivity, epigenetic/regulatory factors, de novo mutations, mosaic occurrence 
or di-/oligogenic inheritance. 
1.3.1.2 Environmental factors 
One hypothesis that explains the occurrence of malformations originating in different time 
windows during development (which is the case in VACTERL association) is that the 
embryo is chronically exposed to a teratogen during this time. It is known that type I, II or 
gestational diabetes in pregnant women increases the risk for vertebral, cardiac and limb 
component features of VACTERL association in the fetus (77). This is suggested to be 
caused by a combination of hyperglycemia, oxidative stress and mitochondrial dysfunction 
(14).  
Teratogens that can cause single component features in VACTERL association include 
anticonvulsants, retinoic acid antagonists and alcohol. Other suggested teratogenic causes are 
for example infertility treatment and contraceptive use in pregnant mothers, but up to date, 
the evidence is weak (14).  
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1.3.1.3 Developmental pathways  
Disturbance in developmental processes that affect formation of all organs involved in 
VACTERL association, for example disturbance in mesodermal proliferation and migration, 
epithelial-to-mesenchymal transition or apoptosis have been proposed. Signalling pathways 
that have been proposed as causative are the SHH, NOTCH and FGF pathways (14, 78). 
1.4 MOSAICISM AND CHIMERISM 
Historically, all cells of an individual have been considered to carry the same genetic content. 
Mosaicism and chimerism represent different variants of a phenomenon in which cells of an 
individual differ in genetic content, with presence of two or more genetically distinct cell 
populations. Mosaicism is known to occur physiologically in development of lymphocytes 
where somatic rearrangements in individual B- and T-cells are responsible for the diversity of 
T-cell receptors and immunoglobulins, fundamental for the adaptive immune system. 
Mosaicism and chimerism are also seen in some genetic diseases and unusual phenotypes.  
1.4.1  Definitions 
Mosaicism refers to the presence of cell populations differing in genetic content, which arise 
after fertilization (post-zygotically) involving one fertilized egg (Fig. 9). Chimerism is 
defined by the fusion of two fertilized eggs into one embryo (Fig. 9).  
1.4.2 Forms of mosaicism 
Mosaicism occurs as the result of a genetic abnormality being introduced after fertilization, 
and since this can happen at any time point in development or postnatal life, the proportions 
and distributions of affected cells vary accordingly. A mutation that occurs in one of the first 
cell divisions after fertilization results in the mutation being present in a large proportion of 
cells of the growing embryo, and may affect all or several different tissues. A mutation 
introduced at a later stage of differentiation may affect fewer, more differentiated cells, for 
example skin or brain tissue. This type of mosaicism is termed somatic mosaicism, while 
mutations occurring only in germ cells are termed germline mosaicism. Germline mosaicism 
is a phenomenon that explains the occurrence of multiple offspring affected by the same 
genetic condition when parents are not carriers of the mutation. Tissue-specific mosaicism, 
with restriction of CNVs to different tissues, has been reported in apparently healthy 
individuals (79). 
The introduction of assisted reproduction techniques, have created possibilities to study 
human embryos at a cellular and molecular level. Studies using single-cell array CGH 
analysis in blastomeres from pre-implantation embryos have revealed a high degree of 
mosaic chromosomal and structural variation at this stage (80, 81), although it seems that a 
proportion of genetically abnormal embryos undergo “self-correction” during the first seven 




One theory explaining this observation is that cell cycle control mechanisms are not fully 
activated during the first cell divisions after fertilization, and that after activation of these 
mechanisms, abnormal cells are mitotically arrested (82). It is also known that self-correction, 
or “rescue”, can occur through loss of abnormal chromosomes, especially for trisomies and 
possibly triploid conceptions, sometimes resulting in uniparental disomy (Fig. 9) (83, 84). 
Another form of rescue is revertant mosaicism, when primary mutations can be self-corrected 
in individual cells, for example in Fanconi anemia and some cutaneous diseases (76, 85).  
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Confined placental mosaicism is a specific type of mosaicism originating in the early 
separation of cells carrying a genetic aberration from normal cells in the embryonic tissues, 
so that the genetically abnormal cells become restricted to placental tissues. This may affect 
fetal growth by placental dysfunction and is also clinically important in chorionic villus 
sampling for prenatal diagnostics, since analysis may show genetic abnormalities not present 
in fetal tissues (86). 
 
It has recently been shown, using breakpoint-specific sequencing in parents of probands with 
apparent de novo CNVs, that in a subset of these families the parents have low-level 
mosaicism for the same CNVs (87).This finding implies a higher recurrence risk than what 
would be estimated if a de novo mutation was present in a single parental germ cell or formed 
in the first cells of the embryo, and the recurrence risk depends on the frequency of the 
mutation in the germline. If a mutation confers a surviving advantage to the cell, the result 
can be an expansion of a mutation-carrying clone in the germline, and an increased 
recurrence risk, possibly as high as a dominant condition (87). Also, low-level parental 
mosaicism for single gene defects are being detected with high-resolution techniques (88). 
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1.4.3 Mosaicism in disease 
The implication of genetic mosaicism for disease phenotypes is difficult to predict in many 
cases, since it is dependent upon timing of the mutation event, cell type/types affected and 
distribution of genetically aberrant cells. However, mosaic forms of disease are generally 
associated with milder phenotypes compared to non-mosaic aberrations.  
The most commonly described form of mosaicism comprises chromosomal aberrations, since 
cytogenetic techniques have enabled detection of these aberrations for a long time. Mosaic 
forms of aneuploidies such as trisomy 13, 18 and 21 usually have less severe phenotypic 
consequences, and mosaic forms of other aneuploidies not seen in constitutional form such as 
trisomy 8, 9, 14, 17 and 22 are found. Mosaic forms of other structural variants such as 
translocations, inversions, ring chromosomes and supernumerary chromosomes are not as 
commonly reported (86). Several mosaic monogenic disorders have been reported during 
recent years often affecting the skin, skeletal and vascular systems and some occurring only 
in mosaic form, such as McCune-Albright, CLOVES and Proteus syndromes (89). 
Mosaicism is also reported in neurodegenerative diseases, normal aging and cancer (89). 
1.4.4 Chimerism  
Whole-body chimerism occurs as the result of a fertilization error when two separate zygotes 
give rise to one embryo (Fig. 9). Other types of chimerism include blood chimerism, when 
blood cells are exchanged between twins, or between mother and fetus and as a result of 
blood transfusion. Chimerism formed from two embryos with the same sex chromosome 
content is not known to cause a phenotype, and may rarely be discovered when blood group 
testing shows evidence of more than one blood group. When two embryos of different sex 
chromosome content form one embryo, genital development may be affected and result in 
ambiguous external genitalia which will lead to clinical genetic investigations. The phenotype 
varies in severity from normal male or female phenotype to different degrees of ambiguous 
genitalia, and is often associated with sterility. Chimerism explains a proportion of 
individuals with ovotesticular DSD, when both ovarian and testicular tissues are present in 
the same individual. Chimerism is proposed to form through different mechanisms; 
tetragametic chimerism, parthenogenetic chimerism, androgenetic chimerism and fertilization 
of the second polar body. In tetragametic chimerism two separate zygotes, formed from four 
gametes with equal quantitative contributions from the mother and the father, fuse. 
Parthenogenetic and androgenetic chimerism involve unequal quantitative contributions from 
mother and father; in parthenogenetic chimerism three of the four genomic contributions are 
of maternal origin while the corresponding proportions have paternal origin in androgenetic 
chimera. Fertilization of the second polar body has not been shown, but is suggested as an 
additional mechanism to give rise to chimeric embryos. 
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2 AIMS 
2.1 OVERALL AIMS 
The overall aims of this thesis were to improve clinical genetic investigations for patients 
with congenital malformations, and at the same time identify genes important in normal 
development of organs. Due to the limited knowledge of genetic factors in the development 
of malformations, clinical genetic counselling for couples with a previous affected child is 
unsatisfactory for families and doctors. An increase in patients with malformations who 
survive and reproduce, due to improvements in surgical and intensive care possibilities, also 
motivates increased research so that better prenatal diagnostics and more accurate estimations 
of recurrence risk can be given to these individuals. 
2.2 SPECIFIC AIMS 
More specifically we wanted to investigate the role of copy number variation in development 
of congenital malformations, and this was attempted by analyzing copy number variations in 
patients with different malformations.  
2.2.1 Investigation of copy number variants using array CGH in patients with 
congenital malformations 
We wanted to systematically investigate copy number variants in patients with congenital 
malformations by analysis with array CGH. Our intent was to investigate if pathogenic copy 
number variants were common causes in patients with malformations and also to identify 
candidate genes important in development of specific organs.  
2.2.2 Mosaicism 
It is known that mosaicism for chromosomal abnormalities often result in milder and more 
varied clinical phenotypes compared to non-mosaic cases. Until the introduction of array 
CGH, the possibilities to investigate smaller aberrations and different tissues have been 
limited due to requirement for technologies with higher resolution and need for tissue culture. 
We wanted to use array CGH analysis in malformed tissue to investigate if genetic mosaicism 
in general, and specifically tissue-restricted mosaicism in malformed tissue, was an 
overlooked cause of congenital malformations due to the difficulty of detection. To 
investigate this possibility we wanted to collect malformed tissue and blood samples from 
individuals with congenital malformations to compare the presence of pathogenic CNVs 
between healthy and malformed tissue.  
2.2.3 VACTERL association 
Chromosomal aberrations and single gene defects have been described in individual patients 
with VACTERL association, but no common cause has been identified in this condition. A 
specific aim was to investigate if copy number variation represented a common cause in 
individuals with VACTERL association, since there is strong belief that this condition with 
multiple malformations has a genetic background. In addition, we wanted to screen for 
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mutations in three specific genes (PCSK5, HOXD13, CHD7) in which mutations had been 
reported in single studies shortly before the start of this study (PCSK5 and HOXD13) or 
where the associate phenotype was overlapping with VACTERL, but where the extent of 
mutations found in patients with VACTERL association was not known (CHD7).  
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3 MATERIALS AND METHODS 
3.1 PATIENTS 
3.1.1 Study I and II 
The two patients described in studies I and II were identified and chosen for research analysis 
after clinical genetic investigations were performed at the Department of Clinical Genetics, 
Karolinska University Hospital, Sweden. 
3.1.2 Study III 
Patients with VACTERL association in study III were identified through the Swedish 
VACTERL Society and from the Pediatric Surgery Department at Astrid Lindgren Children’s 
Hospital, Stockholm, Sweden. Fetal cases fulfilling VACTERL criteria were identified from 
the registries at the section for Perinatal pathology unit at the Karolinska University Hospital 
in Huddinge, Stockholm, Sweden. Patients were included if they fulfilled diagnostic criteria 
for VACTERL association (≥ 3 component features). 
A subgroup of patients with VACTERL-like phenotypes was identified from a previously 
established biobank including DNA from patients with esophageal atresia. Patients with 
esophageal atresia and a minimum of one more component feature of VACTERL association 
were included. 
3.1.3 Study IV 
Patients surgically treated for congenital heart malformations were identified and included 
from the two Swedish centers performing pediatric cardiac surgery; the section for Pediatric 
Cardiology, Queen Silvia Children’s Hospital in Gothenburg and the Pediatric Cardiac 
Surgical Unit, Children’s Hospital at the University Hospital in Lund. The only inclusion 
criterion was that tissue removal was a planned part of the surgical procedure. Patients with 
isolated as well as syndromic phenotypes were included. In total, we received samples from 
33 patients. Ten patients were excluded for different reasons: three patients were excluded 
due to a known syndromic diagnosis (two patients with Down syndrome and one patient with 
CHARGE syndrome), six patients were excluded due to insufficient or inadequate quality of 
material for analysis, and one patient was excluded after analysis when it was revealed that he 
had a brother with the same type of malformation (familial case). Altogether, 23 patients 
were included in the study. One of the patients in this study was also reported in study III 
(V11 in study III/P7 in study IV, array CGH analysis was performed once using DNA from 
heart tissue). 
3.1.4 Study V 
Patients surgically treated for congenital malformations were identified at the Department of 
Pediatric Surgery at Astrid Lindgren Children’s Hospital, Stockholm, Sweden. We used the 
same inclusion and exclusion criteria as in study IV, that patients were included if tissue 
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removal was a planned part of the surgical procedure and that patients with known causative 
diagnoses were excluded, respectively. In total we collected 54 samples from patients with 
varying diagnoses. We received samples from patients with the following diagnoses: 
anorectal malformations (19), esophageal atresia (12), urological malformations (13), biliary 
atresia (3), vascular malformations (3), gastroschisis (1), omphalocele (1), diaphragmatic 
hernia (1) and ovotesticular DSD (1). 
We excluded thirteen patients for whom written consent could not be obtained, five patients 
that had normal array CGH analysis results in previous clinical investigations, one patient due 
to insufficient or inadequate quality of material for analysis and one patient due to previously 
known diagnosis (Down syndrome). After excluding these patients, nine patients were not 
prioritized for analysis, due to low numbers of patients in each group (diaphragmatic hernia, 
vascular malformation, polycystic kidneys, stenosis of the ureter, kidney duplication and 
biliary atresia). Altogether, 25 patients were included in the study. 
3.1.5 Informed consent 
All patients were included after informed consent was given from parents. For fetal cases, 
these were included from a biobank to which parents had given permission for research 
purposes. 
3.2 TISSUE SAMPLES 
Tissue samples from patients with congenital malformations were collected at surgery so that 
tissue removed from the malformed organ as part of the surgical procedure was preserved in 
physiologic saline solution (9 g/L). 
Tissue samples from fetal cases were collected from the biobank of fresh frozen tissue 
samples routinely collected during autopsy proceedings at the Section for Perinatal Pathology 
at Karolinska University Hospital in Huddinge.  
3.3 DNA EXTRACTION 
For DNA extraction, tissue preserved in saline solution was placed on a cell culture dish and 
a piece of desired size (20-40 mg) was cut and weighed. The sample was placed in Cell Lysis 
Solution from the Gentra Puregene Blood Kit (QIAGEN Sciences, Maryland, USA) followed 
by incubation at 65º for 45 minutes and subsequently a 10 minute incubation in a 56º heating 
block after which Proteinase K was added and the sample vortexed vigorously and left over 
night in 56º, after which the regular protocol was followed. 
Genomic DNA was isolated from peripheral blood samples according to standard procedures 
using the Gentra Puregene Blood Kit (QIAGEN Sciences, Maryland, USA).  
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3.4 DNA SEQUENCING (SANGER METHOD) 
The Sanger method for determining a target sequence is a polymerase chain reaction (PCR)-
based method that works by stepwise prolongation of a specific DNA target sequence, using 
target-specific primers and a thermostable DNA polymerase in a mixture of regular 
deoxyribonucleotides and fluorescently labelled dideoxyribonucleotides. The latter molecules 
do not have the hydroxyl group of the carbon at position 3’ of the deoxyribose sugar ring, 
interrupting further prolongation of the chain. The result of the reaction is a multitude of 
fragments of all possible different lengths, with a ddNTP located at the last position. The 
DNA sequence is determined through size-based separation of the fragments and 
identification through detection of wavelengths of emitted fluorescence. 
Identified variants are compared to variants reported in databases with sequence data from 
healthy individuals and characterized according to the effect of the mutation on protein amino 
acid sequence (synonymous/non-synonymous, missense, nonsense or frameshift mutation) 
and splicing. Other factors that influence assessment of a detected single nucleotide variant 
are the degree of conservation of the nucleotide across species and location in functionally 
important sites or domains of the protein. 
DNA sequencing was used in study III to screen the PCSK5, CHD7 and HOXD13 genes for 
mutations in patients and fetal cases with VACTERL association or a VACTERL-like 
phenotype. Primers for PCSK5 screening were designed for the 39 exons found in the 
Ensembl genomic sequence ENSG00000099139, while primers designed at the Department 
of Clinical Genetics, Karolinska University Hospital,  were used in sequencing of HOXD13 
(exons 1 and 2) and CHD7 (exons 2-38).  
Assessment of detected variants was performed with comparison to single nucleotide variants 
listed in dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and by using pathogenicity prediction 
algorithms such as the Alamut v 2.0 software (Interactive Biosoftware, 
http://www.interactivebiosoftware.com). Alignment of protein sequences for PCSK5 was 
performed using the Uni-ProtKB database (http://www.uniprot.org/) and included sequences 
from six vertebrates. 
3.5 MICROSATELLITE MARKER ANALYSIS AND QUANTITATIVE 
FLUORESCENT PCR (QF-PCR) 
The possibility to effectively distinguish alleles and homologous chromosomes, and trace 
them within pedigrees is enabled by the existence of close to seven hundred thousands of 
short tandem repeats, or microsatellites, dispersed throughout the human genome (90). The 
repeats consist of a varying number of contiguous copies of 1-6 bp-units. Due to inexact 
copying of these sequences, there is a high degree of repeat length polymorphisms, with 
around 70% of individuals having varying number of copies in a specific location. To be able 
to distinguish alleles or homologous chromosomes, analyzed markers need to be informative, 
and that probability increases with the proportion of the population that is heterozygous for 
specific markers. The analysis is carried out in a PCR-reaction using one specific fluorescent 
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primer so that multiple single strand copies of the repeat are created. The resulting copies are 
then separated on an automatic sequencer together with a size standard reference so that the 
lengths of the fragments can be determined. The reaction is semi-quantitative, meaning that 
the relative amounts of different alleles can be determined. 
QF-PCR is a specific application of microsatellite marker analysis used in clinical settings to 
identify aneuploidies in chromosomes 13, 18, 21, X and Y. Compared to chromosome 
analysis this PCR-based method is fast (days compared to weeks) but gives no structural 
information. 
Analysis of microsatellite markers and QF-PCR was used to determine the causative 
mechanism behind the different cell populations detected in the patient reported in study I 
and also to determine the parental origin of and mechanism behind the formation of the 
marker chromosome found in the patient described in study II. 
3.6 MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) 
Multiplex Ligation-dependent Probe Amplification is a multiplex PCR-based method used 
for detection of copy number changes in specific chromosomal locations. It can also be used 
for additional applications, for example methylation detection (MS-MLPA). Shortly, MLPA 
starts with hybridization of two adjacent target-specific oligonucleotide probes to patient 
DNA. Successful exponential amplification of the probes is dependent on specific binding of 
both probes to their complementary DNA sequences, so that a subsequent ligation step results 
in the formation of one probe for each target sequence. The designed probes all carry 
identical forward and reverse primer-binding sequences and therefore can be exponentially 
amplified in a subsequent multiplex PCR reaction using one primer pair, on requirement that 
the ligation reaction is successful. PCR-amplified fragments are separated on capillary 
electrophoresis according to size and relative amount detected through fluorescent intensity. 
Intra- and intersample normalization using reference probes and reference samples, so that 
the copy number results measure relative amounts of the target sequences. 
MLPA can be used for confirmation of copy number changes detected with other methods or, 
because of the ease of use, to screen large numbers of patients for specific copy number 
changes. 
In our studies, MLPA was used for confirmation of small copy number variants detected by 
array CGH in study III. 
3.7 CHROMOSOME ANALYSIS 
Analysis of chromosome structure is accomplished by culturing of cells, chemical arrest of 
the cell cycle in metaphase, fixation of chromosomes on glass slides and chromatin staining 
followed by microscopy. With microscopy analysis of metaphase spreads, whole 
chromosome loss or gain (aneuploidy), extra structural abnormal chromosomes such as 
isochromosomes and ring chromosomes, as well as structural chromosomal balanced or 
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unbalanced rearrangements such as deletions, duplications, translocations, inversions and 
insertions can be detected at a resolution limited to around 4-5 Mb depending on the type of 
abnormality and location in the genome. Due to heteromorphisms, interchromosomal 
variations in amount and arrangement of repetitive DNA, chromosomal homologues can 
sometimes be distinguished in chromosome analysis. The method provides structural 
information, provides possibility to analyze single cells and identifies balanced 
rearrangements. The same information is not obtained from more modern methods, such as 
MLPA and array CGH analysis, and chromosomal analysis will likely continue to be an 
important clinical genetic method in the future. An important drawback with this method is 
that the requirement for dividing cells and cell culture (which may take up to 3 weeks) 
renders the method time consuming, and in addition the resolution is low. 
Chromosome analysis was used in individual cases in study I-V to determine the arrangement 
of chromosomal aberrations and to distinguish different cell populations. 
3.8 FLUORESCENT IN SITU HYBRIDIZATION (FISH) 
Hybridization of fluorescently labelled DNA probes of target-complementary sequence to 
denatured meta- or interphase spreads allows the detection of loss or gain of DNA at a higher 
resolution than chromosome analysis. Different types of probes can be used for specific 
purposes such as single copy probes, dual fusion probes, break-apart probes, chromosome 
enumeration probes (CEP) and painting probes. Analysis can be performed on metaphase or 
interphase spreads, with different advantages and drawbacks. Metaphase FISH allows a more 
accurate structural analysis but requires living cells that undergo cell culture to reach the 
metaphase stage. Interphase FISH is convenient to overcome the requirement for cell culture 
and is suitable for analysis on tissues difficult to culture, and is also convenient for analysis of 
a high number of cells in analysis of mosaicism. The resolution of FISH analysis is higher for 
deletions than for duplications. The form of FISH analysis with the highest resolution is 
called fibre FISH and involves denaturation of the protein structures that keep chromatin 
wound together, resulting in a free chromatin chain where targets down to around 5 kb can be 
analyzed. The obvious drawback of FISH analysis is that it is a specific analysis where the 
target analyzed must be chosen beforehand and FISH can thus not be used as a screening 
method. 
FISH analysis was used in studies I, II, IV and V to determine the origin of additional genetic 
material identified by chromosome analysis, to determine rearrangements and to confirm 
aberrations detected by array CGH. 
3.9 ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (ARRAY CGH)  
3.9.1 Principle 
Array CGH is a method that combines screening analysis with high resolution, and has since 
introduced in research and clinical practice become the first choice method in clinical genetic 
investigations of patients with DD/ID, autism spectrum disorders and multiple congenital 
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malformations (91). The method is based on an “array” of several hundred thousand up to 
millions of DNA probes attached to glass slides. The probes can be seen as the equivalent of  
FISH probes, and together represent the whole genome. By analysis with array CGH, DNA 
isolated from patients can be investigated for loss or gain of chromosome material, copy 
number variants, through comparison with DNA isolated from healthy individuals. 
3.9.2 Different types of microarray platforms 
3.9.2.1 Bacterial artificial chromosome (BAC) array  
The first type of microarrays used BAC probes of 200-300 kb, and the resolution for 
detection of CNVs was approximately the same as the size of the probes. BAC array slides 
were produced by a method that involved printing spots of the different probes on to the glass 
slides. The protocols used for BAC arrays involved dye-swap experiments, in which two 
hybridization reactions were performed per patient sample. If the patient sample was labelled 
with Cy3 and the reference with Cy5 in the first reaction, the opposite was done in the second 
reaction to minimize false positive signals.  
3.9.2.2 Oligonucleotide array 
Microarrays using oligonucleotide probes, which are synthesized directly on the glass slide, 
have a considerably higher resolution than BAC arrays. Many oligonucleotide platforms can 
detect aberrations down to a few kb, while the platform with the highest resolution reported 
could detect aberrations down to 0.5 kb (92). 
3.9.2.3 SNP array 
SNP arrays combine detection of copy number variants with genotyping, enabling detection 
of loss of heterozygosity/uniparental disomy in the same experiment. In SNP array 
hybridization reactions, the patient sample is hybridized to the array. Fluorescence intensities 
from the experiment are then compared to a reference dataset to detect copy number variation 
in the patient, and intensities from the different alleles are also compared for each SNP, so 
that genotype can be determined. SNP arrays generally have a somewhat higher resolution 
than oligonucleotide arrays, although the distribution of SNPs is not evenly spread out in the 
genome. However, oligonucleotide probes can be added to SNP arrays to increase coverage. 
SNP arrays have the possibility to detect mosaicism at a lower level than oligonucleotide 
platforms.  
3.9.2.4 Studies I-V 
Array CGH was used in all studies, primarily for CNV screening in studies III, IV and V, but 
also to fine map aberration breakpoints detected by chromosome analysis in study I and II. 
Three different array platforms have been used for array analyses described in this thesis. The 
majority of patients in studies III-V were analyzed using a 180K oligonucleotide platform 
with 60-mer oligonucleotide probes and whole genome coverage, manufactured at Oxford 
Gene Technology (OGT). 
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This platform is used at the Department of Clinical genetics at Karolinska University 
Hospital, Stockholm, Sweden, and has an in-house design with higher density of probes 
within genes and a background of evenly spaced probes over the entire genome. Data 
analysis is performed using the Feature Extraction software for raw data analysis and 
CytoSure Interpret software for CNV analysis. The practical resolution of the platform is 30-
50 kb, varying with probe density in different regions.  
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The patients in studies I and II have been analyzed by a 244K oligonucleotide array from 
Agilent Technologies followed by raw data analysis in the Feature Extraction program and 
CNV detection in the DNA Analytics, both software programs from Agilent Technologies. 
The resolution of this platform is approximately 50 kb.  
Three patients in study III were analyzed with a 38K BAC array containing 38 370 BAC 
clones and manufactured by the Swegene DNA Microarray Resource Center at Lund 
University. For analysis of array data, Bio Array Software Environment (BASE) was used for 
both raw data analysis and CNV detection (93).  
3.9.3 Interpretation of CNVs  
Interpretation of CNV pathogenicity is a well-known challenge due to the widespread 
presence of CNVs in the population and their reduced penetration and variable expressivity 
for associated phenotypes. CNVs can show different types of inheritance; dominant, 
recessive, X-linked or complex and can also unmask recessive alleles on the other 
homologous chromosome. Classically, size, gene content, type of CNV, inheritance and 
presence in databases of healthy or diseased individuals are factors that are assessed when 
considering pathogenicity of a detected CNV. Databases where variants detected in large 
studies of healthy individuals, such as the Database of Genomic Variants (DGV) 
(http://projects.tcag.ca/variation/), or individuals with developmental phenotypes, such as 
DECIPHER (https://decipher.sanger.ac.uk/) and ECARUCA (http://www.ecaruca.net), have 
been created to guide in classification.  
It is also helpful to compare detected variants with variants from analyzed samples in an in-
house database, since detection of some CNVs may be related to platform-specific problems, 
and also these samples may represent a more relevant genetic background. CNVs where 
pathogenicity cannot be determined are termed variants of unknown significance (VOUS) 
(66).  
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4 RESULTS AND DISCUSSION 
4.1 GENETIC CAUSES OF CONGENITAL MALFORMATIONS DETECTED BY 
ARRAY CGH (STUDIES III, IV AND V) 
Screening for pathogenic gene dose alterations in patients and fetal cases with congenital 
malformations using array CGH (study III-V) identified pathogenic aberrations in six patients 
(Table 3). These clearly pathogenic aberrations were detected in patients with syndromic 
phenotypes only, and no pathogenic aberrations were identified in patients with isolated 
malformations. The sizes of the pathogenic aberrations varied from 0.04 Mb to 51 Mb, the 
smallest representing a single gene deletion and the largest a chromosomal aberration. Four 
of the pathogenic variants were large chromosomal aberrations, and three of these were 
identified in males and were the result of unbalanced translocations. The two largest 
imbalances were inherited from fathers that were carriers of the balanced forms of the 
translocations (patients FC14(III) and P15(IV), respectively), while the smaller one had 
occurred de novo in the proband (P4(IV)). In the fourth patient, P24(V), a mosaic 
rearrangement on chromosome 15 was found to have occurred de novo in the patient. Of the 
four detected aberrations, all but the 18;22 translocation should are readily detected by 
chromosome analysis.  
Large chromosomal imbalances are known causes of congenital malformations and since we 
did not perform cytogenetic pre-screening before array CGH analysis, the identification of 
several large structural aberrations is expected. Unbalanced chromosomal translocations are 
usually unique within families and do not represent causes that can be found in many 
patients, although some common features may be identified between patients with 
overlapping aberrations. Candidate disease gene identification from chromosomal aberrations 
becomes rather speculative since the abnormalities usually affect large numbers of genes and 
both duplications and deletions are present in the same patient.  
Two pathogenic findings were not detectable by chromosome analysis, a whole gene FANCB 
deletion in a fetal case (FC10 (III)) and a deletion in the distal 22q11 deletion region in a 
patient with syndromic anal atresia (P12(V)) (Table 3). The FANCB deletion shows X-linked 
recessive inheritance and was transmitted from a healthy mother to a male fetus while the 
22q11.22 deletion was inherited from a healthy father. In this case it remains unclear which 
role this aberration has in the patient phenotype since this deletion is associated with a mild, 
primarily cognitive, phenotype.  
VOUS were detected in 32 patients, and variants in 10 of these patients were chosen based on 
size, copy number type and gene content, and further characterized by investigation of 
inheritance status (Table 4). In one case the CNV turned out to be de novo in the patient 
(patient P24(V)). In two cases the familial samples available were not enough to determine 
inheritance. In seven cases, the aberrations were inherited from apparently healthy parents. 
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VSD ventricular septal defect, EA esophageal atresia.
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EA esophageal atresia, AA anal atresia, TGA transposition of the great arteries, TOF tetralogy of Fallot, CoA coarctation of the aorta, VSD ventricular septal defect, BAV bicuspid aortic 
valve, DD developmental delay, GR growth retardation, ASD atrial septal defect, v. cava sup. vena cava superior.
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Altogether, screening for gene dose alterations in 86 patients with isolated or syndromic 
congenital malformations revealed pathogenic aberrations in 6/87 patients (7%) (Table 5) and 
since pathogenic variants were detected only in syndromic cases, the proportion of 
pathogenic findings was higher when patients with isolated malformations were excluded 
(10% and 20%, respectively, including and excluding the VACTERL group). Pathogenic 
CNVs that would not be detectable by array CGH were found in 2/86 patients (2% and 4% 
including and excluding VACTERL, respectively). VOUS were detected in 32/86 patients 
(37%). A similar study using microarray analysis to investigate copy number variants in 95 
fetal cases with isolated and syndromic congenital malformations reported CNVs >100 kb in 
size in 21% of patients (94). Similarly, in study III-V, 26/86 patients and fetal cases (30%) 
had at least one CNV > 100 kb.  
Considering the phenotypes of patients and fetal cases screened in study IV-V, 58% had 
isolated malformations, which is likely higher than in most clinical settings. It is noteworthy 
that none of the clearly pathogenic findings were identified in patients with isolated 
malformations. Comparisons between patients with isolated and syndromic phenotypes did 
not reach statistical significance, due to small sample sizes and low number of genetic 
findings, although the results may indicate that copy number variants > 50 kb are rare causes 
of isolated malformations. Different proportions of causative findings have been reported 
using array CGH in patients with isolated heart malformations, and the utility of array CGH 
screening in this patient group has been discussed previously (95). The heterogeneity of the 
group “congenital heart malformations” makes conclusions about utility difficult in this 
specific group.  
Nine patients (9/86; 10%) had two or more CNVs > 50 kb and four patients had two or more 
CNVs >100 kb (4/86; 5%). A two-hit model has been proposed for intellectual disability, in 
which one CNV can confer risk for neuropsychiatric disease and the combination with a 
second CNV aggravates the phenotype (96), and it is plausible that a similar mechanism 
could be involved in congenital malformation phenotypes, although this would be difficult to 
prove in individual cases. In two of the four patients with more than one CNV > 100 kb 
(P12(V) and P24(V)), one of the identified CNVs was pathogenic but could not completely 
explain the phenotypes seen in the patients. In the other two cases, it was not possible to 
decide whether the detected variants were associated with the patient phenotypes. It is 
conceivable that the combinations of CNVs are pathogenic, but presently their etiologic role 
cannot be determined in these cases. 
The low proportion of causative findings may partly be explained by the high proportion of 
patients with isolated malformations and the conclusion by us and others that CNVs are 
rarely seen in patients with VACTERL association. The choice of platform naturally 
influences detection rates depending on resolution and robustness. The resolution of the 180K  
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VOUS variant of unclear significance. 
1Correcting total number of patients for one patient that was included in study III and IV. 
2Excluding patients with VACTERL association or a VACTERL-like phenotype in study III. 
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array used in our study is 30-50 kb, and thus we have not detected smaller CNVs which are 
known to be frequent in the genome. Also, patient selection in our studies differs from other 
studies in that we have only included surgically treated patients, so that mosaicism could be 
investigated. This has limited the number of patients included and potentially introduced a 
bias, although the proportion of patients with identified aberrations in our studies is similar to 
those reported in other studies. In addition we did not perform chromosome analysis before 
array CGH analysis, reflecting the finding of several large chromosome aberrations in our 
studies. Importantly, the patient material in our studies is heterogeneous, both within and 
between studies, and this fact likely reduces the possibility to detect aberrations present in 
specific malformations.  
4.1.1 Copy number variants in patients with congenital heart malformations 
Pathogenic gene dose alterations were detected in two patients with heart malformations 
(2/23; 9%) and VOUS were detected in nine patients (9/23; 39%). Based primarily on size 
and gene content, inheritance status was investigated in three patients with VOUS and shown 
to be inherited from unaffected parents and are thus continuously regarded as unclear variants 
that need further study. One of these regions, 6q23.2, may represent a susceptibility region 
for congenital heart malformations and is further discussed in section 4.1.5.1. It is noteworthy 
that inherited variants have been reported as causative in cases of heart malformations (97, 
98).  
Published studies of copy number variants in patients with heart malformations have reported 
similar or higher frequencies, although varying inclusion criteria, definition of copy number 
variants, diagnostic platforms and study design make comparisons difficult (98-102).  
4.1.2 Copy number variants detected in patients with esophageal atresia 
Screening for pathogenic aberrations in esophageal atresia revealed one clearly pathogenic 
aberration and VOUS in all five patients. We identified two novel regions in which gene dose 
alterations could be associated with increased risk for EA, discussed in section 4.1.5.2. 
Genetic causes can presently be identified in around 11-12% of patients with esophageal 
atresia and gene dose alterations are reported in individual cases, while more systematic 
studies have yet to be published (103). One study reporting results from array CGH in seven 
monozygotic twin pairs discordant for esophageal atresia did not report pathogenic variants 
(104). All patients in our material had syndromic EA, which is a possible explanation to a 
high proportion of pathogenic or VOUS identified in our study. The number of patients is too 
low to contribute to the determination of proportion of pathogenic copy number variants in 
patients with EA.  
4.1.3 Copy number variants detected in patients with anal atresia 
In our study of patients with anal atresia, a pathogenic CNV was detected in one patient 
(1/14; 7%) and VOUS were detected in five patients (5/14; 36%). For comparison, probable 
disease-causing CNVs were reported in 17% of patients with anorectal malformations in 
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combination with a CNS malformation (105). In our study, 50% of patients had isolated 
malformations, possibly decreasing the likelihood of detecting pathogenic CNVs.  
4.1.4 Copy number variants in patients with hydronephrosis 
In our study, we did not identify pathogenic CNVs in patients with congenital 
hydronephrosis. Two patients (2/6; 33%) had VOUS. The study group is very small and no 
patients had additional malformations, and thus we cannot draw any conclusions about the 
role of copy number variants in congenital hydronephrosis. 
4.1.5 Interesting copy number variant findings in patients with congenital 
malformations 
4.1.5.1 Deletion at 6q23 in a patient with CoA, VSD and bicuspid aortic valves (BAV) 
A deletion at 6q23.2 was detected in patient P13(IV), with an isolated, combined heart 
malformation including CoA, VSD and BAV. The 0.58 Mb deletion was found to be 
inherited from a mother without a known heart malformation. The deletion overlaps a region 
reported to be associated with hypoplastic left heart syndrome (106), and four of the six 
deleted genes have been reported to be expressed in heart tissue and to be involved in heart or 
vasculature function or development. Homozygous mutations in the ENPP1 gene, encoding 
an ectoenzyme involved in hydrolysis of extracellular nucleotides, cause generalized arterial 
calcification of infancy (OMIM:#208000). A second gene within the 6q23.2 region, ENPP3, 
encodes an isoenzyme of ENPP1, and has no known disease association. Interestingly, the 
mouse homologous gene, Enpp3, shows expression in the second heart field and may be 
regulated by Nkx2.5 (107-109). Further, the MED23 gene encodes a subunit of the large 
mediator complex (MED) involved in transcription activation in which mutations in genes 
encoding other subunits have been reported in congenital heart disease while the subunit 
encoded by MED23 has so far not been associated with heart malformations (110). 
Nevertheless, a Med23
-/-
 mouse model is embryonic lethal and displays disorganization of the 
vasculature (111). The ARG1 gene is expressed in heart and may be linked to coronary heart 
disease (112). A search in the DECIPHER database reveals one patient (patient 251447) with 
an overlapping 7 Mb-deletion and congenital anomalies not including heart malformation.  
It is known that cardiovascular genetics are complicated, with single gene mutations 
associated with heart malformations showing reduced penetrance and varying expressivity, 
and it has been suggested that the causality of CNVs should be evaluated on the basis of gene 
content rather than inheritance and size (113). Considering that four genes in the region seem 
to be involved in heart or vasculature development or function, two of them possibly in the 
same pathway, it seems likely that the variant affects development of the heart and confers 
risk for erroneous morphogenesis with influence of additional genetic or other factors.  
4.1.5.2 Copy number variants at 15q26.3 in patients with esophageal atresia 
Copy number variants at 15q26.3 were detected in three patients with esophageal atresia and 
other features. One was a de novo 0.7 Mb deletion affecting seven genes while the other two 
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were gains (a 0.5 Mb duplication and a 0.4 Mb triplication inpatients P4(V) and P25(V), 
respectively), affecting three genes, and one of them was detected in a healthy monozygous 
twin. The duplication region overlaps with CNVs in the DGV. 
The deletion was detected in patient P24(V) who had partial tetrasomy 15. Esophageal atresia 
has not been described with the tetrasomy 15 genotype previously, drawing attention to the 
15q26.3 region in relation to esophageal atresia. The causal relation of the deletion and EA 
could be one of three possible alternatives: 1) the deletion is unrelated to EA, 2) the deletion 
in combination with tetrasomy 15 can cause EA, or 3) the deletion in itself is causal.  
Combining the results of these three patients and the fact that esophageal atresia is an unusual 
phenotype, the 15q26.3 region seems interesting to study further. Several of the genes 
affected by the detected CNVs are recessive disease genes not associated with esophageal 
atresia, and since the deletion and duplications are not overlapping, it seems likely that a 
putative developmental effect is exerted through disruption of gene expression regulation.  
4.1.6 Summary 
The combined results of study III-V emphasize importance of copy number variant analysis 
in patients and fetal cases with malformations, since variants with high penetrance conferring 
a high recurrence risk are detected. The importance of detection of similar pathogenic 
variants is very high to individual families, with the possibility to provide an explanation, to 
lower recurrence risk estimates and to offer prenatal diagnostics in future pregnancies. Our 
analysis is too small for proportion estimates of causative CNVs in individual malformations, 
but provides further evidence for the contribution of genetic factors in development of 
malformations. 
In patients with isolated malformations, the likelihood of finding pathogenic causes by copy 
number analysis down to 50 kb may be low, although some studies that find no difference 
between de novo CNVs in syndromic and isolated phenotypes provide evidence to the 
contrary (98). Additionally, VOUS which may represent risk factors are detected in a 
substantial proportion of these patients and the impact of such variants will be important to 
investigate to further clarify the etiology behind malformations.  
4.2 MOSAICISM AND CHIMERISM IN PATIENTS WITH CONGENITAL 
MALFORMATIONS (STUDIES I, II, IV AND V) 
A specific aim of this thesis was to investigate the role of genetic mosaicism for copy number 
variants as a cause of congenital malformations. Altogether, 18 patients from study IV and V 
(including ten patients with heart, three patients with EA, three patients with anal atresia and 
two patients with congenital hydronephrosis) were analyzed for pathogenic aberrations or 
VOUS > 50 kb in tissue from the malformation and also in blood samples. We did not detect 
discordance of VOUS patterns between tissue from the malformations and blood in the same 
individuals, and thus our studies do not show that mosaic copy number variation is a common 
underlying cause of congenital malformations. A number of inherent challenges in studying 
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tissue-specific mosaicism as well as specific limitations to our studies, including choosing the 
appropriate tissue for analysis, difficulty of obtaining tissue samples from malformations and 
sensitivity of the analysis method complicate interpretation of the study results.  
So far, no systematic studies comparing copy number variations detected by array CGH 
between tissue from malformations and blood in the same individuals have been published. 
Recently, Bednarczyk et al. reported the presence of five different copy number variants 
detected in esophageal tissue but not detectable in blood in a patient fulfilling criteria for 
VACTERL association (114). Studies of heart malformations investigating genetic 
mosaicism for specific genetic causes using other methods such as DNA sequencing, MLPA 
and FISH have been published (115-130). A number of studies by Reamon-Buettner et al. 
reported somatic mutations in cardiac disease genes identified in formalin-fixed tissue from 
hearts affected by malformations, that other groups were not able to replicate analyzing fresh 
frozen heart tissue. Apart from that, one study where fresh frozen heart tissue was used for 
analysis showed somatic mutations in a subset of patients with sporadic tetralogy of Fallot 
(130). Single studies screening for mosaic forms of X-chromosome aberrations or 22q11-
deletions in cardiac tissue with fluorescent in situ hybridization (FISH) and short tandem 
repeat markers have not reported positive findings (115-117).  
For comparison, mosaicism for CNVs detected in DNA from blood samples in children with 
developmental delay and/or multiple congenital anomalies has been reported with 
prevalences of 0.5-3.74% (86).  
In our studies, an obvious disadvantage is the low number of patients overall and in separate 
diagnostic groups, a result of the difficulty to collect tissue samples from surgical procedures. 
Ethical restrictions to our study allowed collection of discarded material only, and this has 
limited the number of surgical procedures where collection was permitted and also the 
possibility to choose a common source of material. When studying mosaicism, there is a great 
uncertainty as to which tissue to study and conclusions must be drawn accordingly, so that in 
our studies, we could only hope to detect mosaicism present in the whole malformation or 
organ, but not restricted to specific regions. This presumably could exclude aberrations that 
have occurred later during development in more differentiated cells that would affect a 
specific region. In heart development, the difficulty of choosing the appropriate tissue is 
complicated by the hemodynamic effect on heart development so that an initial primary 
abnormally developing structure that affects blood flow can result in secondary 
malformations that may be more prominent (131). 
The resolution of the microarray platform, both regarding size of aberrations and level of 
mosaicism, is important and the 30-50 kb resolution of the 180K oligonucleotide platform 
used in our studies precludes detection of small CNVs. In general oligonucleotide 
microarrays, with minimal mosaicism detection rates around 10-20%, are less sensitive 
compared to SNP arrays and possibly also BAC arrays in detecting low-level mosaicism 
(132, 133). The application of mosaicism filters in the CNV algorithm that we used 
corresponds to a mosaicism level of 15% combined with a size of 5 Mb, although visual 
inspection for smaller aberrations with log2-ratios indicating mosaicism was performed. It is 
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however possible that small aberrations present in <15% of cells have not been detected.  
Somatic CNVs present in more than one tissue (heart, kidney and skin) have been reported in 
a deceased individual without malformations (79), and since CNVs in tissue from congenital 
malformations have not systematically been studied before, we chose to include patients with 
syndromic CHD, and it is possible that this has lowered our chances of finding pathogenic 
mosaicism. 
4.2.1 Aspects of mosaicism 
Different aspects of mosaicism can be highlighted with examples from our studies, for 
example parental mosaicism and inheritance, mechanism of formation, phenotypes and 
prognosis associated with the genotype. 
4.2.1.1 Genotype-phenotype correlations in mosaic disorders 
A known difficulty of genetic counselling in mosaic disorders is the varying phenotype 
associated with mosaic forms of chromosomal aberrations, and this is exemplified by the 
patient described in study I. The underlying explanation is likely the variation of timing for 
the occurrence of the mutation, the cell type affected and the phenotypic effects of the 
aberration on the cell type that will influence distribution and effects of the aberration. In the 
patient of study I, analysis of several different tissues as well as different techniques was used 
to determine the proportion of the trisomic cell population. The patient had a very mild 
phenotype compared to other patients with trisomy 14 mosaicism, despite a detected 
proportion of trisomic cells of up to 30%. Also, it seems that the clinical phenotype in 
trisomy 14 mosaicism is unrelated to the level of mosaicism detected in blood (134). The 
explanation may be a low proportion of trisomic cells in the CNS, or in cell populations 
important during the development of CNS, but this explanation is difficult to prove.  
4.2.1.2 Update of prognosis for non-mosaic chromosomal aberrations 
Several conditions are described in the literature as non-compatible with survival in non-
mosic form, for example trisomy 8, 9, 14, 17 and 22 (135), while constitutional trisomies for 
chromosomes 13, 18, 21 and X can be seen in live-born babies, but with drastically reduced 
survival for trisomy 13 and 18 (90% are reported to die within the first year of life from 
cardiac, renal or neurological complications, or in trisomy 18 from infections). The tendency 
to surgical treatment in this patient category has been restrictive since it has been reported 
that survival is not improved by surgery (136, 137).  
In the patient described in study II, partial tetrasomy 14 was detected. The patient is severely 
affected with multiple malformations, hearing and visual impairment, global developmental 
delay and severe reactions to respiratory tract infections which have required intensive care 
treatment and tracheostomy. Since all previously reported patients with non-mosaic forms of 
the condition have been lethal during infancy, the parents were counselled accordingly. 
Analysis using array CGH, chromosome and FISH analysis did not give evidence of 
mosaicism in this patient. In chromosome analysis, 25 metaphases each from cultured 
peripheral blood lymphocytes and fibroblasts were analyzed, which can exclude mosaicism at 
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the 12% level with 95% confidence in both tissues separately (138). In addition, 100 
interphases from peripheral blood lymphocytes were analyzed without evidence of 
mosaicism. It is still possible that a low-level mosaicism is present, or that a tissue-specific 
pattern for the marker chromosome with lower levels in specific tissue not analyzed by us is 
present. Still, this is the first patient with apparent non-mosaic tetrasomy 14 and long-time 
survival, likely reflecting advances in pediatric intensive care treatment during the last 
decades.  
In light of these advances, it is important to reevaluate survival of patients severely affected 
by chromosomal aberrations, since prognosis is likely based on data accumulated during 
times when surgical techniques and intensive care were less developed. A recent study of the 
effects of surgical treatment of congenital heart malformations in patients with trisomy 13 
and 18 show increased survival in these patients compared to patients who received expectant 
management. The study has limitations such as short follow-up time and a possible bias for 
patients with less severe phenotypes undergoing treatment, but if a subset of patients can 
benefit from surgical repair, it is still important to take into account in determining treatment 
strategies for these patients (139). 
4.2.1.3 Formation of mosaic partial tetrasomy 15 
In study V, an unusual structural variant of the inv dup(15) syndrome was identified in 
patient P24(V), equalling partial tetrasomy 15 in 82% of peripheral blood cells. The cell 
populations harbouring the tetrasomy 15 showed two different alternative rearrangements 
with the extra material located to 15p or a marker chromosome, respectively. In a subset of 
cells, the extra material was lost. From the existing information it is still possible to suggest 
that the most frequent disomic cell population with extra material on 15p was the original one 
and that instability of the arrangement has resulted in formation of a ring chromosome and 
subsequent loss of the ring in a subset of cells. Formation of the more common inv dup(15) is 
described as the result of a U-type exchange mechanism in maternal meiosis (140). The U-
type exchange mechanism cannot alone explain the rearrangement in the patient, and it is 
possible that an initially formed isodicentric marker underwent a subsequent rearrangement 
including non-homologous end-joining of the isodicentric marker and 15p to result in the 
observed karyotype. A similar mechanism has been described to explain the occurrence of 
translocations of 15q, believed to be the reciprocal products of the inv dup(15) chromosome 
(141). Further determination of the mechanism in patient P24(V) is dependent on 
microsatellite marker analysis in parents and proband.  
4.2.1.4 Parental mosaicism 
A 0.40 Mb deletion on 7p21.3 detected in patient P5(IV), a boy who was born with 
transposition of the great arteries and severe hypospadias, was found to be inherited from a 
mother who was reportedly healthy. Parental analysis was performed in an array CGH 
analysis using DNA from buccal cells, and hybridization of maternal against paternal DNA. 
Visual examination of the array result for the parents revealed a mean log2-ratio of -0.16 for 
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the region deleted in the patient, indicative of mosaicism in the mother. Analysis of meta- and 
interphase chromosomes (15 and 332 cells analyzed, respectively) from peripheral blood of 
the patient’s mother showed the deletion to be present in a mosaic state in 16% of 
lymphocytes while analysis in a healthy brother of the patient revealed a normal pattern. The 
inheritance pattern indicates that the CNV could be pathogenic, although further studies need 
to clarify this. The recurrence risk cannot be estimated, both due to the unclear significance of 
the deletion and also due to the limitations to investigating the proportion of oocytes carrying 
the deletion. The family was counselled that they are likely to have an increased risk of 
having an affected child in future pregnancies, and that intensified ultrasound investigations 
are indicated, but presently we may not offer prenatal testing due to the unclear nature of the 
CNV.  
Recently, low-level somatic mosaicism for genetic aberrations in parents was reported to be 
the cause of constitutional genetic syndromes in their offspring (87, 98). This is an important 
discovery since the recurrence rate would be estimated to be considerably higher than if the 
aberrations had occurred de novo, possibly as high as 50% (7). Genetic counselling will be 
difficult if pathogenicity can not be determined for the variant, since a high recurrence risk 
cannot be excluded, but prenatal diagnosis cannot be offered to the family. 
In this case, the deletion interrupts two genes, THSD7A and PHF14, removing the last 19 
exons of THSD7A and the last exon of one splice variant of PHF14. THSD7A encodes a 
protein that has been shown to be important in endothelial cell migrations in zebrafish 
angiogenesis (142) while PHF14 is likely involved in chromatin-mediated transcriptional 
regulation (143). Further studies of this region are needed to determine a potential role in 
development of congenital malformations. 
4.2.2 Chimerism 
To learn more about genetic mechanisms behind malformations, we wanted to specifically 
investigate the mechanism behind the unusual gene dose alterations found in clinical 
investigations of individuals with congenital malformations. In a boy with disorder of sex 
development, mild skin manifestations and normal psychomotor development, chromosome 
analysis revealed a 46,XX/47,XY,+14 karyotype. The parental contributions to genetically 
distinct cell populations in an individual can be determined using microsatellite marker 
analysis and results in this patient revealed chimerism as an underlying cause. Although 
chimerism is not necessarily a cause of phenotypic abnormalities, and is sometimes 
discovered by chance when results of blood group analysis are ambiguous, some types of 
chimerism may result in abnormalities. When the sex chromosome content of two cell 
populations is discordant, varying degrees of disorder of sex development may result, 
although phenotypes can be normal. A second disease-causing mechanism is when one of the 
cell populations shows uniparental disomy (144), leading to imprinting disorders in a varying 
degree in the case of a maternal isodisomic clone, and placental mesenchymal dysplasia in 
case of a paternal clone. The identification of chimerism also provides a unique possibility to 
discover mechanisms involved in human fertilization and the first part of embryogenesis. 
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4.2.3 Summary 
Our studies do not provide evidence for tissue-specific mosaicism as a common cause in 
congenital malformations, however, the sample-size and heterogeneous diagnoses would only 
allow detection if mosaicism was a frequent underlying cause. It is still possible that tissue-
specific mosaicism for CNVs or other types of genetic aberrations are causative, and will be 
detected in future studies using other techniques. The finding of parental mosaicism for a 
putative pathogenic CNV also points to the importance of detecting genetic mosaicism in 
parents, to improve recurrence risk estimations and genetic counselling. 
4.3 CAUSES OF VACTERL ASSOCIATION (STUDY III) 
4.3.1 Copy number variants  
The proportion of pathogenic CNVs identified in patients with VACTERL association was 
5%, which is considerably lower than in syndromic patients from studies IV and V (20%), 
although comparisons are not statistically significant. The finding of a lower proportion of 
pathogenic findings in patients with VACTERL association (study III) compared to patients 
with malformations that were not included based on a VACTERL diagnosis (although some 
patients fulfil VACTERL criteria in studies IV and V), may still support the finding in study 
III and other reports that copy number variants are not common causes behind VACTERL 
association, even compared to patients with multiple malformations. The proportion of 
causative gene dose alterations is similar to the result reported in a study of the same size by 
Hilger et al. who reported 6% causative de novo CNVs (145). With a number of published 
microarray studies, it seems that CNVs are causative in a small subset of patients with 
VACTERL association; however, these singular cases are still important for implications of 
genes and pathways involved in pathogenesis (146-148). It is still possible that small CNVs, 
not detected by current microarray platforms, are important. Notably, analysis in the 19 fetal 
cases included was performed on DNA isolated from tissue samples (lung, spleen, heart or 
liver). It is possible, but not likely, that pathogenic copy number variants could be restricted 
to blood cells or other tissues not sampled.  
It seems that copy number variants can explain a small proportion of cases in the patient 
group, but points to other possible causes of VACTERL that have not been identified yet. 
4.3.2 Single gene defects 
Mutation screening in CHD7, PCSK5 and HOXD13 revealed a pathogenic mutation in CHD7 
in one patient. The de novo CHD7 mutation was identified in a patient with a VACTERL-like 
phenotype, establishing a diagnosis of CHARGE syndrome. The phenotypic overlap between 
VACTERL and CHARGE include esophageal atresia, cardiac defects, anal atresia, renal and 
limb anomalies and our result emphasizes the importance of differential diagnosis in patients 
with these phenotypes.  
The search for a common genetic cause in VACTERL association is often compared to the 
search for and identification of a causative gene in patients with CHARGE syndrome, since 
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CHARGE also occurs sporadically and was shown to be caused by de novo mutations. An 
important difference between the VACTERL and CHARGE phenotypes is that patients with 
CHARGE syndrome have a cognitive impairment which likely results in a low reproduction 
rate in these patients. In contrast neurodevelopmental phenotypes are not seen in patients with 
VACTERL association, and a historically low rate of reproduction is likely due to the 
severity of malformations, especially ARM. With improvement of surgical treatment, it is 
possible that patients with VACTERL association will be more reproductively active and that 
a different recurrence risk could be observed in the future. 
Screening for mutations in PCSK5 revealed three rare missense variants, with genotype 
frequencies in dbSNP of 0.03-2.8%, respectively. The variant with the lowest frequency 
affected a highly conserved Cys residue, resulting in a Cys→Tyr amino acid change, possibly 
disrupting a disulphide bond. The frequency reported is too high to represent a penetrant 
mutation, but could represent a variant with reduced penetrance. The way in which PCSK5 
mutations are believed to cause a VACTERL phenotype is through reduced cleavage of one 
of its’ target proteins, GDF11, which has been shown to participate in regulation of HOX 
genes, long regarded as candidate genes for VACTERL association (74). 
So far, it seems that single gene defects represent causative factors in a subset of VACTERL 
patients. Massive parallel sequencing has not provided a common cause, as in many other 
congenital disorders, although new recessive mutations in TRAP1 were recently reported to 
be present in 2/300 patients with VACTERL association including kidney abnormalities (149, 
150), and so far no VACTERL exome sequencing studies have reported a high proportion of 
de novo mutations. 
4.3.3 Patient selection 
Since VACTERL association is a rare disorder with relatively few genetic findings, we chose 
to include both patients (12) and fetal cases (19) fulfilling diagnostic criteria and patients with 
esophageal atresia and at least one additional malformation in the VACTERL spectrum, not 
fulfilling diagnostic criteria (8), to increase the study group and increase the likelihood of 
finding CNVs with potential candidate genes that could point to specific pathways important 
in development of the malformations seen in VACTERL.  
It is interesting that both pathogenic gene dose alterations and all variants detected in PCSK5 
were identified in fetal cases. All of the included fetal cases, except one, were aborted after 
detection of fetal abnormalities at ultrasound screening, and thus were not spontaneous 
abortions. It may be the case that the fetal phenotypes that are diagnosed with ultrasound are 
more severe compared to the patient phenotypes in our study, and therefore have a higher 
degree of genetic findings, but due to the over-all low frequency of findings this remains 
unclear.  
Inclusion of fetal cases where the neurological phenotype cannot fully be evaluated may 
result in inclusion of cases that, in a postnatal setting, would not have been diagnosed with 
VACTERL because of developmental delay, and this may decrease the likelihood of finding 
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true VACTERL causes in the patients in our study. It is also possible that the patients not 
fulfilling VACTERL criteria in our study would be less likely to have genetic aberrations, 
and that inclusion of these patients lower the expected diagnostic proportion. In our case, the 
inclusion of fetal cases and patients not fulfilling VACTERL criteria makes the results less 
suitable to generalize in terms of frequency, and can be regarded more as a search for 
candidate genes. Given the high number of included fetal cases fulfilling VACTERL criteria 
and pathogenic findings in 11% of these (2/19), one conclusion that may be drawn is that 
genetic analysis in fetal cases are important. 
4.3.4 Summary 
Systematic studies, including our own, have so far not revealed causative single gene defects, 
copy number variants or chromosomal aberrations in a large number of patients. Some 
pathways involved in development of mesodermal structures and mesodermal processes are 
implicated by several studies (14). Because of the intricate signalling network involved in the 
embryologic pattern formation and organogenesis, it is possible that de novo mutations in 
different genes involved in the same network may be responsible, or that oligogenic influence 
is of importance. A theory that should be systematically tested is the role of epigenetic factors 
in VACTERL association. It is also possible that whole genome sequencing will reveal 
mutations. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
In 2008, when we set out to study copy number variants and mosaicism, array CGH had 
relatively recently been introduced as a method used in routine clinical genetic diagnostics, 
and most cases of mosaicism had been diagnosed in the form of aneuploidy by chromosome 
analysis, although examples of mosaic single gene defects were known. During the course of 
these years the technical development has allowed introduction of exome, genome and 
transcriptome sequencing, which can identify the majority of single nucleotide variants and 
structural rearrangements found in a human genome in one single reaction, and in addition 
has the ability to detect mosaicism down to the level of 1% (151). During the next few years, 
massive parallel sequencing will successively replace array CGH as a screening method in 
patients with developmental disease and congenital malformations in research and clinical 
practice. 
We have, along with other research groups, studied the occurrence of pathogenic copy 
number variants in patients with different types of malformations, and the results indicate that 
copy number variants likely represent important and fully penetrant causes in a subset of 
patients, but do not explain the great proportion of isolated or syndromic cases. The 
characterization of inherited copy number variants and determination of their role in genetic 
disease is ongoing and will likely continue. Similarly for single gene defects, the contribution 
of de novo and inherited mutations in congenital malformations will be further investigated 
using massive parallel sequencing. Because of the great number of genes involved in human 
development, the number of possible target genes for mutations is very large and it is possible 
that de novo single gene or copy number mutations, alone or in combination with other 
genetic variants, in a multitude of different target genes are causative. It has been shown that 
aneuploidy is very common in cleavage stage embryos, possibly due to a lower degree of cell 
cycle control, and perhaps single gene mutations are also introduced at this stage. In 
developmental disease, the importance of regulation of gene expression has come more into 
focus and in heart malformations, chromatin regulation has been proposed to provide a new 
important “pathway“ where genetic events can result in disease (152). Since signalling 
networks active during embryonic development are often involved in development of many 
organs, it is likely that they may provide explanations also in other diseases. 
We have investigated if mosaicism for genetic aberrations detected in the malformed tissue 
could be an overlooked cause of malformations. Based on the results of our and other studies, 
mosaicism for different types of aberrations seems more widespread than previously known, 
and is likely to have important roles in many types of disease, although we could not show 
that mosaic copy number changes in malformed organs are common. It is likely that 
underlying mosaicism and chimerism will be encountered more often with new methods that 
can detect very low levels of distinct cell populations and methods that allow genome-wide 
analysis of single cells will contribute to increased knowledge about mechanisms or chain of 
events that lead to mosaic genotypes and phenotypes. 
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In VACTERL association, it seems that a common cause will not be found. It is likely that 
the phenotype can be the result of several different mechanisms that affect mainly 
mesodermal structures. Since large scale sequencing has so far not provided the solution, it is 
possible that the answer is not in the coding sequence. Deregulation of developmentally 
important genes could be involved, either through mutations or rearrangements of regulatory 
units, mutations in non-coding RNAs or through changes in chromatin regulation by genetic 
or environmental influences. Studying altered gene expression in fetuses with diabetic 
mothers in animal models could provide insight into deregulated pathways. Also, the finding 
of a single umbilical artery in a subset of patients with VACTERL association may be a 
somewhat overlooked feature that could provide a clue as to the pathogenic processes that are 
involved (68, 153). 
The knowledge about genomic structure and genetic variation increases continuously, and is 
becoming increasingly complex. It seems that the genetic background in an individual, all the 
different nucleotide variants, microsatellites and copy number variants provide an important 
explanation, but not a solution, to the varying phenotypes seen in the majority of genetic 
disorders. The interplay between this background of variants with varying penetrance in 
different phenotypes, is likely an important cause of sporadic disease, whether it be 
congenital malformations or later-onset phenotypes. 
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6 SAMMANFATTNING PÅ SVENSKA 
Medfödda missbildningar är en viktig orsak till dödlighet och sjuklighet under tiden kring 
födelsen och identifieras hos ca 4% av alla barn som föds i Sverige. Förbättrade 
behandlingsmöjligheter inom barnkirurgi och intensivvård har lett till ökad överlevnad hos 
många barn, men trots detta kan missbildningar medföra livslånga besvär och behov av 
specialiserad sjukvård för drabbade individer. För familjer där barn har fötts med 
missbildningar är möjligheten att få information om bakomliggande orsak, prognos samt 
återupprepningsrisk vid ny graviditet centrala frågor. Ungefär hälften av alla familjer med 
missbildning i kombination med utvecklingsförsening kan få en förklaring till varför deras 
barn drabbats, och för patienter med enbart missbildning är siffran betydligt lägre. Syftet med 
våra studier har varit att öka kunskapen om bakomliggande orsaker till medfödda 
missbildningar för att kunna erbjuda förbättrad klinisk genetisk diagnostik och rådgivning, 
samt att identifiera gener involverade i normal och avvikande organutveckling. 
Viktiga begrepp i våra studier är copy number variation (CNV) och mosaicism. Man har på 
senare år upptäckt att tillskott (duplikation) eller förlust (deletion) av arvsmassa, så kallad 
copy number variation, förekommer hos friska individer som en del av den normala 
variationen mellan människor men att vissa duplikationer och deletioner också kan påverka 
fosterutveckling och orsaka missbildningar eller utvecklingsstörning. Tidigare har sådana 
avvikelser studerats med mikroskopi av celler i delningsfas, men detta har medfört att man 
endast kunna identifiera stora kromosomavvikelser. Med en nyare teknik, array comparative 
genomic hybridization (array CGH), kan mindre sjukdomsorsakande avvikelser 
(duplikationer och deletioner) påvisas. Tekniken används i klinisk genetisk diagnostik för att 
undersöka individer med utvecklingsförsening och/eller medfödda missbildningar.  
Begreppet mosaicism syftar på att man hos vissa individer upptäckt att den genetiska 
uppsättningen i deras celler skiljer sig åt mellan två eller flera grupper av celler, och sådana 
skillnader uppstått efter befruktningen. Man vet numer att mosaicism sannolikt förekommer 
hos många människor utan att det har någon tydlig effekt, men ibland innehåller en av 
cellgrupperna en genetisk avvikelse som leder till sjukdom hos individen, vilket innebär att 
man vid en genetisk analys kan upptäcka tillståndet. Då mosaicism definitionsmässigt innebär 
att en genetisk avvikelse förekommer i en andel av det totala antalet celler i kroppen medför 
det en oftast en ”utspädning” av sjukdomseffekten. En annan mycket ovanlig bakomliggande 
orsak till missbildningar och genetiskt åtskiljbara cellgrupper hos en människa är chimerism 
vilket innebär att ett embryo uppstått genom sammansmältning av två separat befruktade ägg.  
Vi har studerat enskilda fall samt grupper av patienter med olika typer av medfödda 
missbildningar med microarray-teknik samt ett flertal andra genetiska metoder för att 
undersöka vilken betydelse copy number variation och mosaicism har för uppkomsten av 
olika typer av medfödda missbildningar, samt hur vissa deletioner och duplikationer uppstått. 
Vi har utfört analys på arvsmassa isolerad från celler från missbildad vävnad och jämfört med 
celler från blod hos individer med missbildningar, för att undersöka om genetiska avvikelser 
begränsade till missbildad vävnad, alltså mosaicism, kan vara en orsak till missbildningar.  
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Sammanfattning av resultat från våra studier: 
 med array CGH analys har vi hittat sjukdomsorsakande duplikationer och deletioner 
hos 5-8% av patienter med medfödda missbildningar 
 sjukdomsorsakande duplikationer och deletioner förekommer hos en liten andel av 
patienter med VACTERL association  
 analys för duplikationer och deletioner i vävnad från missbildningar har inte påvisat 
mosaicism för copy number variants 
 resultat från molekylära analyser indikerar att partenogenetisk aktivering av ett ägg är 
den bakomliggande orsaken till chimerism hos en patient med 
könsutvecklingsstörning 
 CHARGE syndrom har påvisats hos en patient med symptom liknande de som ses vid 
tillståndet VACTERL association  
 hos en patient med mosaicism för trisomi 14 (förekomst av en extra kromosom 14) 
har analys av ett flertal olika vävnader visat att den avvikande cellpopulationen 
förekommer i proportioner varierande mellan 0 och 30%.   
 vi har rapporterat överlevnad till skolåldern hos en patient med tillståndet tetrasomi 
14 (förekomst av två extra kopior av en del av kromosom 14) i icke-mosaisk form, ett 
tillstånd som tidigare beskrivits som letalt  
Utifrån resultaten av våra studier kan följande slutsatser dras:  
 prognoser för ovanliga genetiska tillstånd med missbildningar kan behöva omvärderas 
då barnkirurgi och barnintensivvård genomgått stora framsteg 
 CHARGE syndrom är ett tillstånd som symptommässigt liknar VACTERL 
association och som är viktigt att särskilja då det har en känd genetisk orsak 
 vilka symptom en patient med en genetisk avvikelse i mosaisk form får är svårt att 
förutsäga, då det sannolikt beror på hur fördelningen av celler med den genetiska 
avvikelsen sett ut under fosterutvecklingen  
 undersökning av duplikationer och deletioner med känslig metodik är viktigt hos 
patienter med medfödda missbildningar, då upptäckt av sjukdomsorsakande 
avvikelser har mycket stor betydelse för enskilda familjer i form av bättre information 
om orsak, prognos och återupprepningsrisk 
 mosaicism för sjukdomsorsakande deletioner och duplikationer förefaller inte vara en 
vanlig orsak till medfödda missbildningar, dock är antalet undersökta fall så litet att 
man inte kan utesluta detta som en sjukdomsorsak 
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